

A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination

Running Title: A scalable COVID-19 serology solution

Karen Colwill¹, Yannick Galipeau², Matthew Stuible³, Christian Gervais³, Corey Arnold², Bhavisha Rathod^{1,4}, Kento T Abe^{1,5}, Jenny H Wang¹, Adrian Pasculescu¹, Mariam Maltseva², Lynda Rocheleau², Martin Pelchat^{2,6}, Mahya Fazel-Zarandi¹, Mariam Iskilova¹, Miriam Barrios-Rodiles¹, Linda Bennett¹, Kevin Yau⁷, François Cholette^{8,9}, Christine Mesa⁸, Angel X Li^{1,10}, Aimee Paterson^{1,10}, Michelle A Hladunewich⁷, Pamela J Goodwin^{1,11}, Jeffrey L Wrana^{1,5}, Steven J Drews¹², Samira Mubareka¹³, Allison J McGeer^{1,10,14}, John Kim⁸, Marc-André Langlois^{2,6*}, Anne-Claude Gingras^{1,5*}, Yves Durocher^{3*}

¹ Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada

² Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada

³ Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, QC, Canada

⁴ Current Address: Treadwell Therapeutics, Toronto, ON, Canada

⁵ Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

⁶ The Centre for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON, Canada

⁷ Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

⁸ National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada

⁹ Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB

¹⁰ Department of Microbiology, at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada

¹¹ Department of Medicine, University of Toronto, Toronto, ON, Canada

¹² Canadian Blood Services, Microbiology, Donation Policy and Studies, Edmonton, and Department of Laboratory Medicine and Pathology, Division of Diagnostic and Applied Microbiology, University of Alberta, Edmonton, AB, Canada

¹³ Department of Laboratory Medicine and Molecular Diagnostics, Division of Microbiology, Sunnybrook Health Sciences Centre; Biological Sciences, Sunnybrook Research Institute; Division of Infectious Diseases, Sunnybrook Health Sciences Centre; and Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada

¹⁴ Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

***Correspondence:**

Marc-André Langlois: langlois@uottawa.ca

Anne-Claude Gingras: gingras@lunenfeld.ca

Yves Durocher: yves.durocher@cnrc-nrc.gc.ca

Lead contact: Anne-Claude Gingras: gingras@lunenfeld.ca

42 **Abstract**

43

44 **OBJECTIVES:** Antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
45 has been instrumental in detecting previous exposures and analyzing vaccine-elicited immune
46 responses. Here, we describe a scalable solution to detect and quantify SARS-CoV-2 antibodies,
47 discriminate between natural infection- and vaccination-induced responses, and assess antibody-
48 mediated inhibition of the spike-angiotensin converting enzyme 2 (ACE2) interaction.

49

50 **METHODS:** We developed methods and reagents to detect SARS-CoV-2 antibodies by enzyme-linked
51 immunosorbent assay (ELISA). The main assays focus on the parallel detection of immunoglobulin
52 (Ig)Gs against the spike trimer, its receptor binding domain (RBD), and nucleocapsid (N). We
53 automated a surrogate neutralization (sn)ELISA that measures inhibition of ACE2-spike or -RBD
54 interactions by antibodies. The assays were calibrated to a World Health Organization reference
55 standard.

56

57 **RESULTS:** Our single-point IgG-based ELISAs accurately distinguished non-infected and infected
58 individuals. For seroprevalence assessment (in a non-vaccinated cohort), classifying a sample as
59 positive if antibodies were detected for ≥ 2 of the 3 antigens provided the highest specificity. In
60 vaccinated cohorts, increases in anti-spike and -RBD (but not -N) antibodies are observed. We present
61 detailed protocols for serum/plasma or dried blood spots analysis performed manually and on
62 automated platforms. The snELISA can be performed automatically at single points, increasing its
63 scalability.

64

65 **CONCLUSIONS:** Measuring antibodies to three viral antigens and identify neutralizing antibodies
66 capable of disrupting spike-ACE2 interactions in high-throughput enables large-scale analyses of
67 humoral immune responses to SARS-CoV-2 infection and vaccination. The reagents are available to
68 enable scaling up of standardized serological assays, permitting inter-laboratory data comparison and
69 aggregation.

70

71 **Keywords:** SARS-CoV-2, antibody detection, antibody neutralization, assay development and
72 standardization, high-throughput screening

73

74 INTRODUCTION

75

76 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has already induced
77 four major waves of infection in Canada, resulting in > 3.2M confirmed infections and > 36K deaths (as
78 of February 25th, 2022 ¹). Overall seroprevalence estimates from natural infection during the pre-
79 Omicron waves were relatively low compared to other countries ^{2, 3}, and protecting the population
80 from coronavirus disease of 2019 (COVID-19) has therefore heavily relied on vaccination. Fortunately,
81 the dramatic acceleration of vaccination in Canada over the past 8 months has decreased
82 symptomatic infections, severe disease, and deaths ⁴; as of February 18th, 2022, 84% of the
83 population 5 years and older were fully vaccinated ⁵.

84

85 However, several important questions remain regarding both infection- and vaccination-induced
86 humoral immunity, including the duration and decay of the immune response, the generation of
87 functional neutralizing antibodies, and the overall differences in humoral responses across groups of
88 individuals with different co-morbidities or following vaccination with different brands and regimens.
89 This information can help guide and prioritize public health programs, such as vaccine booster
90 schedules ⁶.

91

92 Plate-based enzyme-linked immunosorbent assays (ELISAs) are widely used scalable methods to
93 quantitatively assess antibody responses to pathogens, including SARS-CoV-2. Microwells are coated
94 with recombinant SARS-CoV-2 protein antigens, and biofluid samples (e.g. serum, plasma, dried blood
95 spot (DBS) eluate, or saliva) are added (Figure 1a). If antibodies that recognize the antigen are
96 present, they are detected with a secondary antibody, typically linked to an enzyme (such as
97 horseradish peroxidase (HRP)) that elicits a measurable change upon addition of a colorimetric or
98 chemiluminescent substrate.

99

100 Because of their potent immunogenicity, antigens derived from the SARS-CoV-2 spike and
101 nucleocapsid (N) proteins have been most frequently used in serological assays, including those
102 developed by commercial vendors. Full proteins, protein segments, and even peptides have been
103 used in these assays which, combined with their different formats and readouts, yield distinct
104 sensitivity and specificity profiles. This can lead to confusion in interpreting results. For example,
105 conclusions about the persistence of antibodies to the nucleocapsid (N) protein differ depending on
106 the platform used, and commercial vendors often do not disclose the exact amino acid sequence of
107 their antigens ⁷.

108

109 We have previously used ELISAs to show that immunoglobulin (Ig)G (but not IgM or IgA) against SARS-
110 CoV-2 spike, RBD, and N can persist for at least 3–4 months in the serum and saliva of individuals with
111 COVID-19 ⁸, an observation now corroborated and extended by several other studies describing the
112 persistence of circulating IgGs up to 13 months (although with gradual declines; e.g. ⁹⁻¹²). We also
113 showed that the production of neutralizing antibodies capable of preventing interactions between
114 spike (or its RBD) and its target angiotensin converting enzyme 2 (ACE2) could be monitored using a
115 plate-based surrogate neutralization (sn)ELISA ¹³. We demonstrated good correlations between this
116 assay and both spike-pseudotyped lentiviral and authentic SARS-CoV-2 plaque neutralization assays,
117 suggesting that this could provide a scalable and suitable alternative to costly and labor-intensive
118 classical antibody neutralization assessment.

119

120 While laboratory-based ELISAs like ours have been developed around the world, the various sources
121 of antigens and antibodies used by different groups (in addition to batch-to-batch variation within
122 groups) impede national and international comparisons of seroprevalence and vaccine effectiveness.
123 This is further challenged by the lack of agreed-upon reference standards, with the exception of pools
124 of convalescent plasma distributed through the World Health Organization (WHO) to calibrate assays
125 to standardized units¹⁴. Furthermore, assay performance variability over time remains incompletely
126 examined. To address this, we have developed a reproducible and scalable SARS-CoV-2 serology
127 solution using standardized protein reagents and protocols (Figure 1) and independent automated
128 platforms in 2 Canadian laboratories in Toronto and Ottawa. This system has now been used to profile
129 > 150K unique samples, demonstrating its scalability and robustness. Importantly, these reagents and
130 protocols are available to the research community to enable implementation of these assays across
131 laboratories.

132
133

134 Results

135

136 Reagent production

137 To facilitate comparison of SARS-CoV-2 serology results across Canada, we sought to develop and
138 validate a scalable ELISA-based assay that leverages the mammalian protein expression expertise of
139 the National Research Council of Canada (NRC) Human Health Therapeutics Research Centre. We
140 optimized the production and purification of SARS-CoV-2 proteins (spike trimer, spike RBD, and N
141 from the original Wuhan-Hu-1 strain) to generate large-scale high-purity batches of antigens (Figure
142 1b, Supplementary figures 1 and 2, Supplementary table 1). These were fused with purification tags
143 ((His)₆ and FLAG, with or without a Twin Strep-tag) and expressed in Chinese Hamster Ovary (CHO)
144 cells either as stably transfected pools (spike) or through transient transfection (RBD, N)^{8, 15}. Antigens
145 were purified by Immobilized Metal Affinity Chromatography (IMAC), with one or two additional
146 purification steps performed for RBD and N (StrepTrap XT columns and/or preparative size exclusion
147 chromatography, SEC). The spike and RBD proteins were highly pure when analyzed by SDS-PAGE
148 (Figure 1b). By analytical SEC, spike eluted as a major (>95% integrated area) symmetrical peak of 490
149 kDa (consistent with its trimeric structure) with < 3% hexamers/aggregates, and both versions of RBD
150 (encoding amino acids 319–541 and 331–521, respectively) eluted as single peaks with >95%
151 integrated area. For purified N, some truncated forms were visible by SDS-PAGE/Coomassie staining;
152 however, by SEC, it eluted as a major (>99% integrated area) peak with no apparent larger aggregates.
153 Estimation of molecular weight of N was not possible by multiangle light scattering (MALS), but based
154 on the SEC elution volume, it appears to be ~300 kDa. This is consistent with the formation of
155 tetramers or hexamers by recombinant coronavirus N, as reported by others¹⁶. For recombinant
156 protein production in CHO cells, post-purification yields ranged from 25 mg L⁻¹ for RBD 331–521 to
157 370 mg L⁻¹ for spike (Supplementary table 1).

158

159 The antigen toolbox was supplemented with a detection reagent, namely an anti-human IgG
160 monoclonal antibody (IgG#5) expressed as a HRP fusion in-frame to the heavy chain (HC) C-terminus.
161 This reagent was developed to address an issue common to HRP-based detection reagents from
162 commercial sources, which are usually polyclonal anti-IgG antibodies conjugated to HRP post-
163 purification. These commercial reagents display variability due to the nature of the polyclonal serum
164 used by each supplier, as well as the ratio of conjugated HRP molecules per antibody. IgG#5 was
165 produced by co-transfecting HC and light chain (LC) expression vectors in CHO cells. As shown in

166 Figure 1, the purified antibody consists of a predominant band at ~110 kDa, which represents the full-
167 length HC-HRP fusion peptide. A minor band at ~55 kDa is likely a form of the HC lacking HRP
168 (confirmed by western blotting with an anti-mouse-Fc antibody (data not shown)), while the LC
169 presents as a smear between 25 and 37 kDa. Because of this heterogeneity, purified IgG#5-HRP gave a
170 convoluted profile by analytical SEC (Supplementary figure 1).

171

172 To have a common reference that enables intra- and inter-lab comparisons of SARS-CoV-2 antibody
173 responses, we also generated recombinant anti-spike antibodies. Compared to pools of serum or
174 plasma from convalescent patients, these offer the advantage of being renewable, scalable, and
175 defined in sequence. Three recombinant single-domain antibodies (VHHs) were selected: VHH72 is a
176 SARS-CoV and SARS-CoV-2 cross-reactive antibody described in Wrapp *et al.*¹⁷, and NRCov2-04 and -
177 20 are SARS-CoV-2 spike-binding VHHs developed in-house at the NRC. All antibodies were produced
178 in CHO cells and purified on a MabSelect SuRe column. VHH sequences were fused at the C-terminus
179 to Fc1X7 (an antibody-dependent cellular cytotoxicity (ADCC)-attenuated variant of human Fc) to
180 produce dimeric proteins upon secretion from CHO cells. VHH72-Fc eluted as a single symmetrical
181 peak of 102 kDa with < 2% aggregates, NRCov2-04-Fc eluted with a major peak of 67% integrated
182 area and a peak of 90 kDa, and NRCov2-20-Fc as a single peak of 100 kDa with < 2% aggregates
183 (Supplementary figures 1 and 2; Supplementary Table 1). The toolbox was further supplemented with
184 a biotinylated ACE2 protein (used for snELISA), which was purified on both IMAC and Strep-Tactin XT
185 Superflow columns and elutes from SEC as a single peak of 90 kDa (Supplementary figure 1).

186

187 While the goal is ultimately to have a fully NRC-sourced protein toolbox, the current set of reagents is
188 complemented by a commercial anti-N antibody to quantify the anti-N response (see Methods). As
189 described below, the assays can also be repurposed for IgA/M monitoring with commercial secondary
190 antibodies and matching reference antibodies for calibration.

191

192 **Direct detection ELISA**

193 We previously developed ELISAs in 96-well colorimetric or 384-well chemiluminescent formats to
194 assess the persistence of antibody responses⁸. This first version relied on small-batch research-grade
195 or commercial reagents that are not readily scalable for nationwide surveillance studies. Here, we
196 have first benchmarked the NRC reagents described above, and defined the optimal antigen and
197 secondary antibody amounts in a 384-well automated format (see Methods). The NRC protein toolkit
198 was independently optimized on automated platforms in Toronto (a Thermo Fisher Scientific F7
199 platform) and Ottawa (a Hamilton system), leading to minor variations in the optimal amounts of
200 antigens and detection reagents, in part due to differences in the detectors on each system
201 (Supplementary table 2). While the platforms can be used to generate full titration curves from serum
202 samples, single-point measurements more readily enable scaling up to thousands of samples and
203 have been used in most large-scale studies to date.

204

205 Toronto platform: The optimal dilution for single-point ELISAs was established using a 10-point four-
206 fold titration series starting with 0.25 μ L positive control serum per well (a 1:40 dilution, which is the
207 amount used previously⁸; Supplementary figure 3). A prozone (hook) effect was noted at the 1:40
208 dilution for samples with higher antibody levels, suggesting that a lower concentration was desirable.
209 We performed receiver operating characteristic (ROC) analysis on a set of 300 negative pre-COVID19
210 samples (collected prior to November 2019) and 211 PCR-confirmed convalescent patients (>14 d
211 post-symptom onset) at three different concentrations (Supplementary figure 4), optimizing for an

212 amount of serum that would work with all three antigens. The 0.0625 μ L per well serum condition
213 was selected for single-point ELISA based on a reduced hook effect on spike (compared to the highest
214 amount) and better specificity and sensitivity characteristics on its RBD (compared to the lowest
215 amount). A final ROC analysis combining data from a second replicate at 0.0625 μ L per well at a false
216 positive rate of $< 1\%$ revealed sensitivities of 94%, 92%, and 81% for spike trimer, RBD, and N
217 respectively (Table 1, Supplementary figure 4b). Importantly, replicates from experiments conducted
218 8 weeks apart were highly correlated ($\rho > 0.87$ for all three antigens, Figure 2a), similar to our
219 previous observations⁸, giving us confidence in conducting large-scale cohort studies.

220
221 Ottawa platform: Early optimizations of the serological assay to identify the serum dilution within a
222 linear range with the lowest non-specific reactivity to the negative serum were performed using the
223 manual colorimetric ELISA (Supplementary figure 5). The colorimetric assay was used to test the
224 performance of the HRP-conjugated antibodies, including six different anti-human IgG conjugate
225 antibodies provided by the NRC (Supplementary figure 6a) with different characteristics and enzyme
226 conjugation strategies (e.g. HRP fusion vs conjugation). While all candidates offered good detection,
227 IgG#5—a direct HRP fusion—was selected for further assays, based on its superior quantitative
228 capacity and extremely low non-specific reactivity within a standard reaction time (Supplementary
229 figure 6b). This reagent was also compared to commercial polyclonal and monoclonal secondary
230 antibodies for the detection of anti-spike, -RBD, and -N IgG in DBS samples (see below and
231 Supplementary figure 7c). While all antibodies correctly identified negative and positive DBS samples,
232 IgG-#5-HRP offered the greatest distinction between the negative and positive distributions. To
233 maintain a high level of specificity, the secondary antibody concentration and the nature of substrate
234 were modified between the manual and automated ELISAs (see Supplementary table 2 for the final
235 concentrations).

236 237 **Setting positivity thresholds in seroprevalence studies**

238 One concern with establishing thresholds based on a single sample set is that over time and with
239 variations in sample type (venipuncture vs. capillary blood collection, different collection tubes and
240 handling conditions, etc.), the background of the assay may change, affecting the threshold for
241 reporting positives. In Toronto, we monitored the negative controls (blanks, pre-COVID-19 negative
242 sera, commercially purified IgG, $n = 1,320$ for spike and 1,248 for N and RBD) used in 23 experiments
243 conducted over 4 months. We calculated a threshold of 3 SDs from the mean of the log distribution of
244 these controls and compared it to the thresholds established by ROC analysis (Figure 2b). The
245 thresholds were very similar for N and spike, but the 3 SD range was more stringent for the RBD,
246 decreasing the likelihood of false positive calls. We therefore adopted a threshold of 3 SDs from the
247 mean of these controls for each antigen and recalculated our performance characteristics (Table 1).
248 At this threshold, the specificity for RBD increases to 100% with a slight decrease in sensitivity to 89%,
249 spike retained the same sensitivity and specificity (99% and 94%, respectively), whereas N's sensitivity
250 decreased from 81% to 79% with 99% specificity. The same strategy was applied to IgM and IgA to
251 define stringent thresholds (Supplementary figure 8, Supplementary table 4).

252
253 Even with these conservative thresholds, an unacceptable number of false calls may be made in low
254 seroprevalence situations (as in Canada, particularly during the first waves of infection). This is shown
255 by the negative samples (red dots in Figure 2a) that passed the thresholds in individual assays.
256 Importantly, these pre-COVID negatives were only ever positive in one test, in contrast to true
257 positives, which tended to pass the positivity thresholds of ≥ 2 tests, consistent with the high

258 correlation between the assays ($\rho > 0.84$ for all three combinations, with the highest correlation
259 between spike and its RBD; Figure 2c). Our final determination of sample positivity in seroprevalence
260 settings therefore requires that it exceeds the thresholds of at least 2 out of 3 antigens. As can be
261 seen in Figure 2C, this strategy eliminates the false positive calls for the individual antigens (red dots)
262 while retaining similar sensitivity (combined specificity of 100% and sensitivity of 91%).
263

264 **Harmonization between platforms and testing the WHO standards**

265 To compare our ELISA-based assays with others, we tested them using WHO international reference
266 panel 20/268, comprised of five samples (Negative, Low, Mid, High, and Low S/High N; Figure 3,
267 Supplementary figure 9) and expressed the results in BAU mL⁻¹ by comparing signals to the WHO
268 International Standard (20/136). For this, we used single-point measurements from dilutions that
269 were within the linear range of the International Standard curve (Toronto) or the median of three
270 dilutions (Ottawa). For all five samples, the median results from both labs were highly correlated ($\rho =$
271 1 for spike and N, 0.9 for RBD) and were between 0.5–2 fold of the geometric mean (red line with half
272 arrows) reported in a multi-lab comparison by WHO¹⁴. Importantly, by applying a conversion formula
273 to our relative ratios for expression in BAU mL⁻¹ (Figure 3d, Supplementary Table 3), our results can be
274 readily compared to other national or international efforts. Using this formula, plasma or serum
275 seropositivity thresholds for IgG are 34, 31, and 11 BAU mL⁻¹ for nucleocapsid, RBD, and spike
276 respectively (Toronto). When samples are diluted 1:2560, the assays can detect values up to 5344,
277 4454 and 1500 BAU mL⁻¹ for N, RBD, and spike respectively.
278

279 **DBS testing**

280 For serosurveillance, it is important to capture broad swaths of the Canadian population, and at-home
281 sample collection is ideal for this, especially during times of lockdown or restricted movement. DBSs
282 are easier to collect, more stable at room temperature, and considered non-hazardous when dried^{18,}
283¹⁹. We optimized the elution concentrations for both the colorimetric and automated assays (see
284 Methods), and then compared the results of DBS samples and matching plasma samples using
285 reference samples created by the National Microbiology Laboratory (NML; panel 1, with a total of 26
286 different DBSs and matching plasma samples; Supplementary figure 10a). Using NML panel 3, we also
287 found a high correlation in signal between different punch sizes at a constant ratio of punch area to
288 elution volume (Supplementary figure 10b).
289

290 However, despite this high correlation between the two sample types, the higher relative ratios of
291 DBS samples compared to plasma or serum samples shifted the positive and negative density
292 distributions, making direct application of the plasma/serum thresholds inappropriate for scoring
293 seropositivity using DBSs (Supplementary figure 10c). ROC analysis was therefore performed in
294 Toronto and in Ottawa on panel 4, also supplied by the NML (Tables 2 and 3, Supplementary figures
295 11 and 12), yielding sensitivities of 98% for spike and its RBD and 92% for N at a 1% false positive rate
296 threshold in Toronto. By requiring 2 out of 3 calls to be positive, the specificity increased to 100% and
297 the sensitivity was 98%. In Ottawa, at a 3% FDR, the assays achieved 100% sensitivity for each antigen
298 with false positive rates of 2% for spike, 1% for its RBD, and 6% for N. When requiring 2 out of 3 calls
299 to be positive, specificity and sensitivity were both 98%. In the final protocol, we opted to use two 3
300 mm (3.2 mm in Ottawa) punches, as this enables more flexibility and reproducibility when collections
301 are not ideal (which would be typical of self-collection). The minimal sample requirement means the
302 analysis can still be performed even when full DBSs are not provided.
303

304 **snELISA**

305 We previously reported an ELISA-based test that functions as a surrogate to more complex
306 neutralization assays employing live viruses, at least with regards to assessing antibodies that prevent
307 the interaction of spike with the ACE2 receptor¹³. In this snELISA, a sample is added to a plate coated
308 with RBD or spike antigens (Figure 1a). Instead of a secondary antibody, biotinylated ACE2 is added
309 followed by streptavidin-HRP. If antibodies from the sample recognize the antigen, they will block
310 biotinylated ACE2 from binding, leading to decreased signal when HRP substrate is added. The
311 biotinylated ACE2 was first tested in a manual colorimetric assay using recombinant antibody and
312 known negative and positive samples (Supplementary Figure 13). Both the full-length spike trimer and
313 the RBD domain (319–541 construct) were comparable to prior reagents produced at smaller scale.
314 The assay was then transferred to an automated 384-well chemiluminescent format. Using a panel of
315 samples from the Canadian Blood Services and from two donors after one or two doses of the
316 BNT162b2 (aka Comirnaty; Pfizer-BioNTech) mRNA vaccine, the dose response curves between spike
317 and its RBD were significantly correlated ($\rho = 0.90$; Figure 4A, Supplementary figure 13).

318
319 The snELISA was also implemented on the Ottawa automated platform. Titration of the coating
320 antigen, streptavidin-HRP polymer, and luminescent substrate were performed with varying amounts
321 of biotinylated ACE2 to establish the concentrations with optimal sensitivity, appropriate dynamic
322 range, and a minimized hook effect at high ACE2 concentrations (Supplementary figure 14). The final
323 concentration of ACE2 per well was established at 6.5 ng, using 100 ng/well of coated antigen and the
324 substrate diluted 1:2. Using these conditions, we were able to generate consistent neutralization
325 efficiency measurements with serum and plasma (Figure 4B, Supplementary figure 15), enabling us to
326 calculate effective concentration for 50% inhibition (EC50) values for convalescent sera and in sera
327 from doubly vaccinated individuals. We also tested a panel of 121 positive and six negative samples
328 from the *Stop the Spread Ottawa* study as single point measurements at a 1:5 dilution using spike as
329 the antigen (Figure 4C). Convalescent samples ranged from 0–100% inhibition, with a median value of
330 70%. The six negative samples ranged from 0–32% inhibition with a median of 26%, consistent with
331 our previous observation that pre-pandemic samples can achieve partial inhibition of the spike-ACE2
332 interaction due to cross-reactivity of antibodies targeting seasonal coronaviruses²⁰. For DBS samples,
333 four 3 mm punches eluted in 100 μ L of PBS from a double-vaccinated individual showed measurable
334 neutralization activity (Supplementary figure 15); however, we were unable to measure neutralization
335 in DBS samples from convalescent or singly vaccinated individuals (in contrast to serum). Therefore,
336 while it is possible to detect neutralization activity from DBSs, this is limited to samples with high
337 neutralizing activity. Additionally, DBS samples might not be ideal for quantitative neutralization
338 measurements, as sample quality, paper saturation, and disc punching consistency can interfere with
339 the reproducibility and reliability of the results.

340
341 The final development performed with the snELISA was to correlate binding inhibition to international
342 units (IUs) of the WHO International Standard (Figure 4D). By titrating the standard, we established
343 the correlation between binding inhibition and IUs within the linear range of the curve, with 0.251 IUs
344 being required to inhibit ACE2-spike interaction by 50% (EC50). We then tested the WHO reference
345 panel 20/268 by snELISA using spike (Ottawa) or RBD (Toronto) as antigens (Figure 3E). For the low,
346 mid and high samples, results from Toronto and Ottawa were between 0.5–2 fold of the geometric
347 mean (red line with half arrows) reported in a multi-lab comparison by the WHO¹⁴. For the low S,
348 high N sample, there was no inhibition of ACE2 binding in the snELISA using RBD as the antigen, in
349 contrast to the snELISA using full-length spike which detected inhibition levels similar to the WHO

350 study. Given the numerous different protocols and strategies that are being used to measure
351 neutralizing antibodies such as spike-pseudotyped lentiviral assays, plaque reduction neutralization
352 tests (PRNT) and the snELISA, transforming the data to IUs will enable more robust cross-laboratory
353 and cross-assay correlations to be performed.

354 355 **Visualization of the results of seroprevalence and vaccination studies**

356 As defined above, the assays optimally use the IgG responses to three antigens (spike, RBD, N) to
357 report seropositivity resulting from SARS-CoV-2 infection. To illustrate how vaccination cohorts differ
358 from infected cohorts, we re-plotted a subset of the data from our training set (positives and
359 negatives) as pairwise comparisons of spike and N on scatterplots, with the color intensity mapping to
360 that of RBD (Figure 5A). We also replotted data from a cohort of vaccinated patients on dialysis ²¹
361 prior to vaccination and 6 weeks afterward (Figure 5B). As expected, the infected cohort contained
362 samples largely positive for all three antigens tested, while the vaccinated cohort largely consisted of
363 samples positive for spike and its RBD, but negative for N, which is not targeted by vaccines used in
364 Canada. This type of visualization helps define individuals with evidence of infection from those with
365 antibodies resulting from vaccination.

366 367 **Discussion**

368
369 In this paper, we describe a toolkit and protocols for both SARS-CoV-2 serosurveillance and
370 vaccination response profiling that we applied to populations studies in Canada. We have validated
371 these reagents, produced and made available by the NRC, in two separate laboratories. The results
372 can be expressed as relative ratios or can be converted into international units (BAU mL⁻¹ for antibody
373 detection, IU mL⁻¹ for antibody neutralization) to facilitate comparisons between labs and with studies
374 proposing correlates of protections based on these units ²². We validated antibody detection and
375 surrogate neutralization assays in 96-well format (manual colorimetric assays) and on two different
376 384-well automated chemiluminescent platforms, enabling these reagents to be used at small-scale in
377 laboratories with basic equipment and in dedicated high-throughput facilities equipped with different
378 automation equipment.

379
380 All vaccines approved for use in Canada (also in USA and Europe) use spike as the immunogen ²³⁻²⁵.
381 For those who have been vaccinated, responses to spike (and its RBD) are expected, whereas a
382 response to N is only expected after infection. Thus, it is of value to focus on these two orthogonal
383 readouts when detecting and characterizing immune responses ²⁶. Adding the spike RBD as a third
384 antigen increases specificity [of the three antigens, it is the least conserved in coronaviruses ²⁷⁻²⁹] and
385 provides insight into possible protection, as it is also the antigen most correlated with neutralization
386 potential ^{13, 30, 31}.

387
388 By definition, single point assays must make compromises in defining antigen/antibody/detection
389 antibody amounts to ensure that a large fraction of measurements are within the linear range of
390 quantification. Here, we have optimized the concentrations of the serum/plasma/DBS eluates used to
391 capture the most positives (i.e. convalescent individuals) possible without inducing a hook effect. Still,
392 in samples with very high antibody levels (including those from healthy individuals following two
393 doses of vaccine), the measured antibody levels will saturate the assay, thereby preventing their
394 accurate measurement. When the relative amounts of antibodies detected across samples is

395 important to measure, expanded dilutions should be performed (note that this drastically decreases
396 assay throughput and increases costs). As a compromise, in vaccinated cohorts, we routinely perform
397 two-point dilution (16-fold difference) assays that expand the range of concentrations that can be
398 measured in the linear range of quantification, from 1 BAU mL⁻¹ to 1500 BAU mL⁻¹ for spike, and from
399 3 BAU mL⁻¹ to 4454 BAU mL⁻¹ for RBD.

400
401 We also optimized our seropositivity thresholds to limit false positives, both by providing a stringent
402 definition of positivity in each assay, and by requiring that this positivity threshold be met in two
403 separate assays to establish overall positivity in seroprevalence studies. While we felt this was
404 essential to avoid inflating the positive calls in low prevalence settings, it may affect the overall
405 sensitivity of the assays, especially following recent infection/vaccination (where seroconversion for
406 anti-spike often precedes that of RBD and N⁸) or as antibody levels decay. Other limitations stem
407 from the selection of antigens, as those used in these assays are from the original Wuhan-Hu-1 strain,
408 and it is possible that decreased sensitivity occurs when testing patients infected with variants,
409 especially Omicron which has 30 amino acid substitutions (15 within the RBD), three small deletions
410 and one small insertion in the spike coding sequence³² [though our initial results with non-vaccinated
411 Omicron-infected convalescents indicate detection of anti-RBD IgG on this assay; optimization of
412 assays based on Omicron sequences is ongoing]. Lastly, as assays using N generally have poorer
413 specificity and sensitivity (at our defined thresholds) than RBD- and spike-based assays, they may not
414 be ideal as a stand-alone method to define vaccine breakthrough infections, unless serial blood
415 samples are available (in which case an increase in anti-N levels would indicate that an infection has
416 occurred). Further assay development will include additional viral antigens not contained in the
417 vaccines to increase the detection sensitivity for antibodies produced in breakthrough infections. The
418 control over reagent production and quality, and the flexibility of the ELISA platforms to
419 accommodate new antigens also provide a rapid route to testing immune responses to variants. All
420 reagents and protocols are publicly available to enable the rapid deployment of these assays.

421
422 The validated automated ELISA assays described here are currently being used in multiple Canadian
423 studies (with >150,000 unique samples profiled to date). These include large serosurveys that monitor
424 the global (and regional) humoral response (from both infection and vaccination) in the Canadian
425 population, including the Canadian COVID-19 Antibody and Health Survey from Statistics Canada²,
426 seroprevalence studies with Canadian Blood Services^{33, 34}, the Action to Beat Coronavirus study³⁵,
427 and the Canadian Partnership for Tomorrow's Health study³⁶. Additionally, these assays are used in >
428 30 studies focused on infection and/or vaccine responses across different cohorts, e.g. in persons
429 predicted to have a weaker immune response (based, for example on age³⁷ or health conditions³⁸),
430 or who are likely to be exposed to infection from the workplace. The results of the assays have
431 critically helped informed public health decisions. Based on, e.g. a weak response to vaccine in older
432 adults or patients on dialysis^{21, 39}, or the decline in antibody levels post-dose 2 in residents of long-
433 term care homes^{40, 41}, prioritizations were made for second doses, vaccine type was recommended,
434 or additional doses were accelerated in the populations studied. Combined with other studies
435 coordinated by the COVID-19 Immunity Task Force (CITF)⁴², our serology studies help guide Canada's
436 response to the COVID-19 pandemic.

437

438 **Methods**

439

440 **Protein production**

441 **Spike trimer:** The SARS-CoV-2 spike ectodomain construct (SmT1) from the Wuhan-Hu-1 strain with
442 S1/S2 furin site mutations, K986P/V987P prefusion-stabilizing mutations, and human resistin as a
443 trimerization partner¹⁵ was produced using stably transfected Chinese Hamster Ovary (CHO) pools
444 (CHO^{BRI/2353™} cells) and purified as described⁸. To prepare reference material aliquots for distribution
445 by the National Research Council of Canada (NRC) Metrology Research Centre, the bulk purified
446 protein was formulated in PBS supplemented with 10 mM HEPES sodium salt. After aliquoting and
447 one freeze-thaw cycle, protein integrity and purity were assessed by sodium dodecyl sulfate-
448 polyacrylamide gel electrophoresis (SDS-PAGE; Figure 1B) and analytical size-exclusion ultra-high
449 performance liquid chromatography (SEC-UPLC; Supplementary figure 1, Supplementary table 1). SEC-
450 UPLC was run on an Acquity H-Class Bio UPLC system (Wyatt Technology, Santa Barbara, CA, USA) in
451 phosphate buffered saline (PBS) + 0.02% Tween-20 on a 4.6 × 300 mm Acquity BEH450 column (2.5
452 μm bead size; Waters Limited, Mississauga, ON, Canada) coupled to a miniDAWN Multi-Angle Light
453 Scattering (MALS) detector and Optilab T-rEX refractometer (Wyatt).

454
455 **Nucleocapsid:** N cDNA (corresponding to amino acids 1–419 of YP_009724397, Wuhan-Hu-1 strain)
456 was synthesized by GenScript (Piscataway, NJ, USA; using *Cricetulus griseus* codon bias) with a C-
457 terminal FLAG-Twin-Strep-tag-(His)₆ tag and cloned into the pTT5[®] expression plasmid (NRC) to create
458 NCAP⁴³. Expression by transient transfection of CHO^{BRI/55E1™} cells was performed using a previously
459 described high cell density method¹⁵. Since a significant proportion of N was released from
460 transfected cells despite high viability, it was purified from the culture supernatant. Following
461 centrifugation and filtration, supernatant harvested 7 d post-transfection was purified by immobilized
462 metal affinity chromatography (IMAC) on a Ni Sepharose Excel column (Cytiva, Vancouver, BC,
463 Canada). The column was washed with 50 mM sodium phosphate buffer (pH 7.0) containing 25 mM
464 imidazole and 300 mM NaCl, and N was eluted with 50 mM sodium phosphate buffer (pH 7.5)
465 containing 300 mM imidazole and 300 mM NaCl. N was further purified by affinity chromatography
466 on a StrepTrap XT Chromatography Column (Cytiva) equilibrated in Buffer W (100 mM Tris pH 8.0, 150
467 mM NaCl). The column was washed with Buffer W and bound protein was eluted with Elution Buffer
468 (Buffer W supplemented with 50 mM biotin and 1 mM ethylenediaminetetraacetic acid (EDTA)).
469 Purified N was buffer exchanged into Dulbecco's PBS (PBS) using a CentriPure P100 Gel Filtration
470 Column (Apex Scientific, Maynooth, Ireland), sterile-filtered through a 0.2 μm membrane, and stored
471 at -80°C. For preparation of reference material aliquots (NCAP-1) for distribution by National Research
472 Council of Canada (NRC) Metrology, the bulk purified protein was processed through an additional
473 buffer exchange in 50 mM Tris-HCl pH 8.0 supplemented with 150 mM sodium chloride. N integrity
474 and purity was analyzed by SDS-PAGE and analytical SEC-HPLC, which was run in PBS supplemented
475 with 200 mM arginine on a 5 × 150 mm Superdex 200 HR column (Cytiva).

476
477 **RBD:** Amino acids 331–521 of the SARS-CoV-2 spike protein (YP_009724390.1, Wuhan-Hu-1 strain)
478 were cloned into the pTT5[®] vector using EcoRI and BamHI. The construct encodes an N-terminal
479 human interleukin 10 signal peptide (MHSSALLCCLVLLTGVRA) followed by a Twin-Strep-tag II-(His)₆-
480 FLAG tag fused to the RBD N-terminus. The construct was expressed by transient gene expression in
481 CHO^{BRI/55E1™} cells as described above¹⁵. Clarified culture supernatant harvested 8 d post-transfection
482 was purified by IMAC on Ni Sepharose Excel columns as above. The IMAC eluate was buffer-
483 exchanged using NAP-25 columns (Cytiva) into PBS before a second affinity purification step using
484 Strep-Tactin XT Superflow (IBA Lifesciences, Göttingen, Germany), following the manufacturer's
485 instructions. The pooled eluate (de-salted into PBS and concentrated) was applied to a Superdex-75
486 gel filtration column (Cytiva). SEC fractions containing RBD with low levels of high-molecular-weight

487 contaminants were pooled. The second RBD construct (RBD³¹⁹⁻⁵⁴¹) consists of amino acids 319–541
488 with a C-terminal (His)₆-FLAG tag. The protein was expressed and purified as described for RBD³³¹⁻⁵²¹,
489 except the Strep-Tactin XT purification step was omitted.

490
491 RBD and N antigens were compared against previously validated antigens produced by the Rini and
492 Sicheri laboratories, respectively, and described in ^{8,13}.

493
494 **Recombinant antibody production:** VHH and mAb sequences were synthesized by GenScript using *C.*
495 *griseus* codon bias and cloned into the pTT5[®] plasmid. The llama single domain antibody (VHH)
496 VHH72 was described previously (PDB entry 6WAQ_1) ¹⁷. Additional VHHs (NRCov2-04 and NRCov2-
497 20) were isolated in-house from llamas immunized with recombinant SARS-CoV-2 trimeric spike
498 ectodomain Smt1 (Supplementary figure 2). VHH sequences were fused to an antibody-dependent
499 cell-mediated cytotoxicity (ADCC)-attenuated human IgG1 Fc domain (hFc1X7, from patent US 2019
500 352 383A1) to generate VHH72-Fc, NRCov2-04-Fc and NRCov2-20-Fc. The anti-human-IgG
501 monoclonal antibodies (mAbs) IgG#5 and IgG#6 were derived from mice immunized with human IgG;
502 heavy chain (HC) and light chain (LC) variable domain sequences (VH and VL) were fused to mouse
503 IgG2a and mouse kappa LC constant domain sequences, respectively, to express full-length mAbs. The
504 HC was fused in-frame at its C-terminus with ferric HRP (PDB: 1W4W_A) to create IgG#5-HRP and
505 IgG#6-HRP. These mAbs were also tested as HRP conjugates (rather than HRP fusions) as described in
506 Supplementary figure 6. For protein production, VHH or mAb HC/LC (50:50 w/w) plasmids were
507 transfected into CHO^{BRI/55E1™} cells using PEI-Max transfection reagent (Polysciences, Warrington, PA,
508 USA) as described previously ^{13,15}. Clarified 0.2 µm-filtered supernatants were loaded on 5 mL HiTrap
509 MabSelect SuRe columns (Cytiva) equilibrated in PBS, and the columns were washed with PBS prior to
510 antibody elution with 100 mM citrate buffer, pH 3.6. The eluted antibodies were formulated in PBS by
511 buffer exchange using NAP-25 columns. Purified proteins were quantified based on their absorbance
512 at 280 nm and analyzed by analytical size-exclusion on an Acquity BEH200 column (Waters) by UPLC-
513 MALS system (as described above for the spike trimer) or on a 5 × 150 mm Superdex 200 HR column
514 (Cytiva) coupled to a high-performance liquid chromatography (SEC-HPLC) system (Waters).

515
516 **Biotinylated ACE2 production:** The human ACE2 (UniProtKB-Q9BYF1) cDNA was synthesized by
517 GenScript and optimized for expression in CHO cells. The construct encodes a human interleukin 10
518 signal peptide (MHSSALLCCLVLLTGVRA) followed by a Twin-Strep-tag II-(His)₆-FLAG tag on the N-
519 terminus of the mature ACE2 receptor ectodomain (amino acids 20–613). A biotin acceptor peptide
520 (BAP) sequence (GLNDIFEAQKIEWHE) was added in-frame at the ACE2 C-terminus. The cDNA was
521 cloned into pTT5[®] using EcoRI and BamHI. The ACE2-BAP cDNA was expressed by transient gene
522 expression in CHO^{BRI/55E1™} cells as described ¹⁵ with the addition of 5% (w/w) pTT5[®]-BirA (an
523 *Escherichia coli* biotin ligase) expression plasmid as described previously ⁴⁴. Clarified culture
524 supernatant harvested 8 d post-transfection was purified by IMAC on Ni Sepharose Excel columns as
525 described for N above. The IMAC eluate was buffer-exchanged using NAP-25 columns into PBS before
526 a second affinity purification step using Strep-Tactin XT Superflow. The pooled eluate (buffer-
527 exchanged into PBS as above) was stored at -80°C. Biotinylated ACE2 from the NRC was compared
528 against biotinylated ACE2 produced in the Rini lab and previously described in ¹³.

529
530 **Participant recruitment and study approval**

531 All research was performed in accordance with Canada's Tri-Council Policy Statement: Ethical Conduct
532 for Research Involving Humans. External samples and data were transferred via Materica and Datal

533 Transfer Agreements as appropriate. Samples were de-identified prior to transfer to the assay
534 laboratory.

535 For Toronto cohorts: Negative control serum samples were from patients enrolled in cancer studies
536 pre-COVID-19 (prior to November 2019; Mount Sinai Hospital (MSH) Research Ethics Board (REB)
537 studies #01-0138-U and #01-0347-U), which were archived and frozen in the Lunenfeld-Tanenbaum
538 Research Institute (LTRI) Biobank. Convalescent serum samples were obtained from in- and out-
539 patients with polymerase chain reaction (PCR)-confirmed COVID-19 by the Toronto Invasive Bacterial
540 Diseases Network in Toronto and the regional municipality of Peel, Ontario (REB studies #20-044
541 Unity Health Network, #02-0118-U/05-0016-C, MSH). Specimen-only Canadian Blood Services (CBS)
542 serum donations were collected from individuals who met one or more of the following criteria: (a)
543 indicated they had a SARS-CoV-2-positive PCR test, (b) a declaration of having been a close contact of
544 a COVID-19 case, (c) a travel history and clinical presentation compatible with COVID-19, and (d) signs
545 and symptoms compatible with COVID-19. ELISAs were conducted at the LTRI with MSH Research
546 Ethics Board (REB) approval (study number: 20-0078-E). Samples from vaccinated individuals were
547 obtained from Sunnybrook Health Sciences Centre (REB study #4814, Sunnybrook, #21-0049-E, MSH)
548 and from MSH (REB study #20-0144-A).

549 For Ottawa cohorts: Pre-pandemic serum and plasma samples were collected between April 2015 and
550 December 2019 from diverse sources, including the Eastern Ontario Regional Laboratory Association
551 (EORLA) and the Ottawa Hospital (TOH). Pediatric samples were acquired from the BC Children's
552 Hospital Biobank (BCCHB) in Vancouver, BC, Canada (REB#: H-07-20-6009). Pandemic samples were
553 collected from longitudinal studies of severe and mild hospitalized cases of COVID-19 (REB # H-04-20-
554 5727 and # H-11-20-6172), and from a surveillance study of at-risk and convalescent individuals called
555 *Stop the Spread Ottawa* (REB # H-09-20-6135) at the Ottawa Hospital Research Institute and the
556 University of Ottawa.

557

558 **Sample collection, handling, and viral inactivation**

559 Serum and plasma collection: Samples were collected using standard phlebotomy procedures at
560 collection sites or self-collected by individuals after capillary puncture. In Toronto, inactivation of
561 potential infectious viruses in plasma or serum was performed by incubation with Triton X-100 to a
562 final concentration of 1% for 1 h prior to use^{8,45}. Serum and plasma samples collected and processed
563 in Ottawa did not require viral inactivation, as they were handled and tested within the University of
564 Ottawa CL2+ biocontainment facility.

565

566 DBS preparation: Samples were prepared at the National Microbiology Laboratory of Canada (NML) as
567 in⁴⁶. For panels 1–3, plasma from SARS-CoV-2 antibody-positive COVID-19 convalescent donors (MSH,
568 Toronto) and SARS-CoV-2-negative donors (NML, Winnipeg) were used to generate matched plasma
569 and contrived DBS samples. For contrived DBS samples, fresh SARS-CoV-2 antibody-negative blood
570 was centrifuged, the plasma was removed, and the red blood cells were resuspended 1:1 in antibody-
571 positive plasma and spotted (5 × 75 µL) onto Whatman 903 Protein Saver Cards (GE Healthcare,
572 Boston, MA, USA), which were dried at room temperature overnight, then stored with desiccant in
573 gas-impermeable bags at -80°C until testing. SARS-CoV-2 antibody-negative blood was spotted
574 directly from EDTA Vacutainer tubes onto DBS cards. For panel 4, both positive and negative blood
575 samples were spotted directly from EDTA tubes. All matched plasma and contrived DBS samples were
576 tested using the anti-SARS-CoV-2 ELISA IgG kit (EUROIMMUN, Lübeck, Germany), according to the
577 manufacturer's instructions, to verify that donors were either positive or negative for SARS-CoV-2
578 antibodies prior to shipping to Toronto and Ottawa.

579

580 DBS handling: Toronto: Samples from DBS cards were punched manually using a 6 mm punch or in a
581 semi-automated manner using a BSD600 Ascent puncher (BSD Robotics, Brisbane, QLD, Australia)
582 with the indicated punch size. We first compared 6 mm circle punches from contrived DBSs and
583 matching plasma samples (Supplementary figure 10) by eluting the punches in 250 μL PBST plus 1%
584 Triton X-100 (0.226 $\text{mm}^2 \mu\text{L}^{-1}$ eluate). After this initial test, to ensure sufficient eluate to test all three
585 antigens from 1 or 2 3-mm punches, we selected a final elution ratio of 0.176 $\text{mm}^2 \mu\text{L}^{-1}$ elution buffer
586 (i.e. 80 μL for 2 \times 3 mm punches). Eluted samples were centrifuged at 1,000 $\times g$ for 30 s before
587 transfer to 96-well plates. Eluates were diluted 1:4 in 1.3% Blocker BLOTTO (Thermo Fisher Scientific,
588 Waltham, MA, USA) to a final concentration of 1% in PBST, unless otherwise specified.

589

590 DBS handling: Ottawa: Samples from DBS cards were punched manually or in a semi-automated
591 manner using a DBS puncher (PerkinElmer, Woodbridge, ON, Canada; 3.2 mm discs) or a BSD600
592 Ascent puncher (BSD Robotics; 3 mm discs) and eluted in 100 μL per disc PBS + 1% Triton X-100 for up
593 to 16 h (minimum 4 h) in 96-well U-bottom plates on a shaker at room temperature. Elution
594 optimization data are presented in Supplementary Figure 7. Eluates were centrifuged at 216 $\times g$ for 2
595 min and diluted 1:2 in 2% milk + PBST for a final concentration of 1% milk in PBST.

596

597 **Colorimetric direct ELISAs: Toronto protocol**

598 Manual colorimetric ELISAs were adapted from assays described in ^{8, 13}. Antigens (spike trimer, RBD
599 331–521, and N) at the indicated amounts (in ng, see Supplementary table 2 for optimized amounts)
600 were diluted in 50 μL PBS and adsorbed onto a 96-well high-binding polystyrene Greiner Bio-One
601 plate (Thermo Fisher Scientific, #655061) overnight at 4°C. Wells were washed three times with 200
602 μL PBST and then blocked with 200 μL 3% w/v milk powder (BioShop Canada Inc., Burlington, ON,
603 Canada, #ALB005.250) in PBST for 1–2 h at room temperature. Samples were diluted as indicated in
604 50 μL of 1% w/v (final) milk powder in PBST and added to each plate. A standard curve of recombinant
605 antibody was added to each plate in 50 μL 1% w/v milk powder in PBST at the indicated
606 concentrations. For spike and its RBD, the recombinant antibodies used were VHH72-Fc (NRC; see
607 above), human anti-spike S1 IgG (clone HC2001, GenScript, #A02038), human anti-Spike S1 IgM (clone
608 hIgM2001, GenScript, #A02046), and human anti-spike IgA (clone CR3022, Absolute Antibody, Oxford,
609 United Kingdom, #Ab01680-16.0). For N, the antibodies used were human anti-nucleocapsid IgG
610 (clone HC2003, GenScript, #A02039), anti-nucleoprotein IgM (CR3018 (03-018), Absolute Antibody,
611 #Ab01690 -15.0), and anti-nucleoprotein IgA (CR3018 (03-018), Absolute Antibody, #Ab01690 -16.0).
612 Negative control antibodies purified from human serum (final 1 $\mu\text{g mL}^{-1}$; human IgG, Sigma-Aldrich,
613 Oakville, ON, Canada, #I4506; human IgM, Sigma-Aldrich #I8260, human IgA, Sigma-Aldrich, #I4036)
614 and pools of positive and negative sera from 3–4 patients were added to each plate in 50 μL 1% w/v
615 milk powder in PBST for quality control and to enable cross-plate comparisons. Samples were
616 incubated for 2 h at room temperature, and wells were washed three times with 200 μL PBST. Anti-
617 human secondary antibodies (recombinant anti-human IgG#5-HRP, goat anti-human IgG Fcy-HRP
618 (Jackson ImmunoResearch Labs, West Grove, PA, USA, #109-035-098), goat anti-human IgM fc5u-HRP
619 (Jackson ImmunoResearch Labs, #109-035-129), and goat anti-human IgA α chain-HRP (Jackson
620 ImmunoResearch Labs, #109-035-127) were added to the plate at the indicated dilutions in 50 μL 1%
621 w/v milk powder in PBST and incubated for 1 h at room temperature. Wells were washed three times
622 with 200 μL PBST, then 50 μL of 1-Step Ultra TMB-ELISA Substrate Solution (Thermo Fisher Scientific,
623 #34029) was added for 15 min at room temperature. The reaction was quenched with 50 μL Stop
624 Solution for TMB Substrates (Thermo Fisher Scientific, #N600). The plates were read at 450 nm in a

625 Cytation 3 Cell Imaging Multi-Mode Reader (BioTek Instruments Inc., Winooski, VT, USA). Blank values
626 (the mean of the blanks in each 96-well plate) were subtracted from all raw reads prior to data
627 analysis.

628

629 **Colorimetric direct ELISA: Ottawa protocol**

630 Manual colorimetric ELISAs were modified from the assay described in ⁴⁷. High protein-binding
631 Immulon 4 HBX clear 96-well plates (VWR International, Mississauga, ON, Canada, #62402-959, note
632 these plates have also been tested and validated in Toronto) were coated with 50 μL of 2 $\mu\text{g mL}^{-1}$
633 antigen (spike, RBD 319–541, and N diluted in sterile PBS (WISENT Inc, St-Bruno, QC, Canada, #311-
634 010-CL)) were incubated at 4°C on a shaker overnight. The next day, coated plates were washed three
635 times with 200 μL of PBST and blocked with 200 μL of 3% w/v skim milk powder in PBST for 1 h at
636 room temperature on a shaker at 700 rpm. The blocking buffer was removed, and plates were
637 washed three times with 200 μL PBST. Serum and plasma samples were diluted in 1% w/v skim milk
638 powder in PBST. An isotype-specific standard curve was included on each plate to enable cross-plate
639 comparison: anti-SARS-CoV-2 S CR3022 Human IgG1 (Absolute Antibody, Ab01680-10.0), anti-SARS-
640 CoV-2 S CR3022 Human IgA (Absolute Antibody, Ab01680-16.0), or anti-SARS-CoV-2 S CR3022 Human
641 IgM (Absolute Antibody, Ab01680-15.0). Serum/plasma samples, standard curve, positive and
642 negative controls, and blanks (100 μL /well in 1% w/v skim milk in PBST) were added and incubated for
643 2 h at room temperature on a plate shaker at 700 rpm. The plates were washed four times with 200
644 μL PBST, HRP-linked secondary antibody diluted in 1% milk in PBST (50 μL) was added, and the plate
645 was incubated for 1 h at room temperature on a shaker at 700 rpm. The final isotype-specific
646 secondary antibodies used were anti-human IgG#5-HRP (Supplementary figure 6), anti-human IgA-
647 HRP (Jackson ImmunoResearch Labs, 109-035-011), and anti-human IgM-HRP (Jackson
648 ImmunoResearch Labs, 109-035-129). Plates were washed four times with 200 μL PBST and
649 developed using 100 μL of SIGMAFAST OPD Tablets (Sigma-Aldrich, P9187) dissolved in 20 mL Gibco
650 Water for Injection for Cell Culture (Thermo Fisher Scientific, A1287301, final concentration of 0.4 mg
651 mL^{-1} OPD, 0.4 mg mL^{-1} urea hydrogen peroxide, and 0.05 M phosphate-citrate, pH 5.0). After 10 min
652 of incubation in the dark, the reaction was stopped with 50 μL of 3 M HCl and the absorbance was
653 measured at 490 nm using a PowerWave XS2 Plate Reader (BioTek Instruments). Wells filled with
654 dilution buffer were used as background controls and their reads were subtracted from serum values.
655 Colorimetric assay optimization data are presented in Supplementary figures 5 and 6.

656

657 **Chemiluminescent direct ELISA: Toronto protocol and optimization**

658 Automated chemiluminescent ELISAs were adapted from assays first described in ⁸, and performed
659 using liquid dispensers (Biomek NXP (Beckman, Indianapolis, IN, USA), Multidrop Combi (Thermo
660 Fisher Scientific)) and a washer (405 TS/LS LHC2 (Biotek Instruments)); all wash steps included four
661 washes with 100 μL PBST on a Thermo Fisher Scientific F7 Robot System at the Network Biology
662 Collaborative Centre (nbcc.lunenfeld.ca). All incubations were performed at room temperature.
663 Antigen (spike trimer, RBD 331–521, or N) at the indicated amounts (ng) were diluted in 10 μL PBS
664 and dispensed into the wells of a 384-well LUMITRAC 600 high-binding polystyrene Greiner plate
665 (Thermo Fisher Scientific, #781074). The plate was centrifuged at 233 $\times g$ for 1 min to ensure even
666 coating, incubated overnight at 4°C, and washed. Wells were blocked with 80 μL of 5% Blocker
667 BLOTTO for 1 h and then washed. Samples and controls (as in the colorimetric assay) were diluted as
668 indicated in a final concentration of 1% Blocker BLOTTO in PBST, and 10 μL was added to each well
669 from 96- or 384-well source plates. Plates were incubated for 2 h, and wells were washed with PBST.
670 Secondary antibodies (as in the colorimetric assay) were diluted as indicated in 1% Blocker BLOTTO in

671 PBST and 10 μ L was added to each well. After incubation for 1–2 h, the wells were washed and 10 μ L
672 of ELISA Pico Chemiluminescent Substrate (Thermo Fisher Scientific, #37069, diluted 1:4 in ddH₂O) was
673 dispensed into each well and mixed at 900 rpm for 10 s. After a 5–20-minute incubation, plates were
674 read on an EnVision 2105 Multimode Plate Reader (PerkinElmer) at 100 ms/well using an ultra-
675 sensitive luminescence detector.

676
677 Protein reagents from the NRC (described above) were first optimized in the 96-well colorimetric
678 manual assay using recombinant antibodies and serum samples from CBS (Supplementary figure 16).
679 The final amount of antigen per well was then scaled down by 3.5–4-fold to migrate to 384-well
680 format for the automated assay. Two concentrations of secondary antibody IgG#5-HRP (0.09 and 0.18
681 μ g mL⁻¹) were assessed using dilution curves of the VHH72-Fc antibody (to detect spike and its RBD) or
682 an anti-N antibody (to detect N; Supplementary figure 17), and the best concentration (0.18 μ g mL⁻¹)
683 was further tested on a dilution series of 32 serum samples provided by CBS (Supplementary figure 3).
684 We also tested anti-RBD NRCoV2-04-Fc and NRCoV2-20-Fc recombinant calibration antibodies, which
685 were comparable to VHH72-Fc as reference curves (Supplementary figure 17). For IgA and IgM
686 detection, reagents were first tested in the colorimetric assay (Supplementary figure 8). For
687 chemiluminescent assays, 10 μ L of goat anti-human IgM-HRP (1:10,000; 0.80 ng/well) or goat anti-
688 human IgA-HRP (1:12,000, 0.66 ng/well) were used as secondary antibodies.

689 690 **Chemiluminescent direct ELISAs: Ottawa protocol and optimization**

691 Automated chemiluminescent ELISAs were based upon and optimized from assays first described in
692 ⁴⁸, and performed using MicroLab Star robotic liquid handlers (Hamilton, Reno, NV, USA) and a 405
693 TS/LS LHC2 plate washer (Biotek Instruments; all wash steps included four washes with 100 μ L PBST)
694 at the University of Ottawa, Faculty of Medicine (Roger Guindon Hall). All incubations were done at
695 room temperature with shaking at 500–700 rpm. Antigens (spike, RBD 319–541, and N) were diluted
696 in PBS and dispensed into the wells of a 384-well high-binding polystyrene Nunc plate (Thermo Fisher
697 Scientific, #460372) at a final amount of 50 ng/well. The plates were centrifuged at 216 \times g for 1 min
698 to ensure even coating, incubated overnight rocking at 4°C, and washed. Wells were blocked with 80
699 μ L of 3% w/v skim milk powder dissolved in PBST for 1 h and then washed. Samples and controls were
700 diluted as indicated to a final concentration of 1% w/v skim milk powder in PBST and 10 μ L was added
701 to each well from a 96-well source plate. Plates were incubated for 2 h and wells were washed.
702 Secondary antibodies (as in the colorimetric assay) were diluted as indicated in 1% w/v skim milk
703 powder in PBST and 10 μ L was added to each well. After incubation for 1 h, the wells were washed
704 and 10 μ L of ELISA Pico Chemiluminescent Substrate (diluted 1:2 in MilliQ H₂O) was dispensed into
705 each well. After a 5 min incubation with shaking, plates were read on an Neo2 plate reader (BioTek
706 Instruments) at 20 ms/well and a read height of 1.0 mm.

707 708 **Colorimetric snELISAs: Toronto protocol and optimization**

709 The snELISA assay was performed as described ¹³ with the indicated antigens and ACE2. All wash steps
710 included four washes in 200 μ L PBST. RBD 319–541 or spike was adsorbed onto 96-well high-binding
711 polystyrene Greiner Bio-One plates (Thermo Fisher Scientific, #655061) at 100 or 200 ng/well,
712 respectively, in 50 μ L PBS and incubated overnight at 4°C. Plates were washed, then blocked for 1–1.5
713 h at room temperature with 200 μ L 3% bovine serum albumin (BSA; BioShop Canada Inc., SKI400.1).
714 After washing, serum or plasma was added to the plate at the indicated concentrations in 50 μ L 1%
715 BSA in PBST (final concentration) and incubated for 1 h. Wells were washed and incubated with 50 μ L
716 of biotinylated recombinant ACE2 as indicated for 1 h. After washing, wells were incubated with 44 ng

717 Streptavidin-Peroxidase Polymer, Ultrasensitive (Sigma-Aldrich, S2438) for 1 h. The resultant signal
718 was developed and quantified with TMB-ELISA in an identical manner to the colorimetric direct
719 ELISAs. Due to day-to-day variations in signal, all optical density at 450 nm (OD₄₅₀) values were
720 normalized to the OD₄₅₀ of the well without serum or antibody for each sample. All values are
721 expressed as ratios.

722

723 **Chemiluminescent snELISAs: Toronto protocol**

724 The automated snELISA assay was performed on the same F7 platform as the direct detection ELISA
725 with the same washing protocol and incubation temperature. Greiner 384-well Lumitrac 600 plates
726 were coated with RBD 319–541 (34 ng/well) or spike (50 ng/well) following the same protocol as for
727 direct detection. Before each of the next four steps, the plates were washed four times with PBST: 1)
728 the wells were blocked with 80 µL 3% BSA in PBST for 1 h; 2) Plasma or serum sample was dispensed
729 at the indicated dilutions in 10 or 20 µL and incubated for 2 h; 3) 10 µL of ACE2-BAP (2.08 ng/well in
730 1% BSA in PBST) or ACE2-Rini (17 ng/well in 1% BSA in PBST) was added to each well and the plates
731 were incubated for 1 h; 4) 10 µL of Streptavidin-Peroxidase Polymer, Ultrasensitive (15 ng/well in 1%
732 BSA in PBST) was added to each well and the plates were incubated for 1 h. Addition of ELISA Pico
733 Chemiluminescent Substrate and reading on the EnVision 2105 Multimode Plate Reader (PerkinElmer)
734 were performed as for direct detection. All values were normalized to blanks (with no samples added)
735 on the same 384 well plate.

736

737 **Chemiluminescent snELISAs: Ottawa protocol**

738 The surrogate neutralization ELISA first described in ¹³ was adapted and optimized for compatibility
739 with the Hamilton MicroLab STAR robotic liquid handler. The methods for plate washing steps,
740 incubations, and data acquisition were as described for the automated chemiluminescent ELISA. 384-
741 well high-binding polystyrene Nunc plates (Thermo Fisher Scientific, #460372) were coated with 100
742 ng/well of spike or RBD 319–541, centrifuged in a plate spinner to ensure even coating, and incubated
743 overnight with rocking at 4°C. Plates were washed, 80 µL of blocking solution (3% w/v skim milk
744 powder in PBST) was added to each well, and the plates were incubated for 1 h at room temperature
745 on a shaker at 700 rpm. During the blocking step, serum/plasma samples or DBS eluates were diluted
746 in skim milk powder in PBST to a final milk concentration of 1% w/v. For single-point neutralizations,
747 samples were diluted 1:5, or to calculate the half maximal effective concentration (EC₅₀), the samples
748 were titrated using a 5-point curve (1:5, 1:25, 1:125, 1:625, 1:6,250). To facilitate quality control,
749 downstream analysis, and cross-plate comparisons, standard curves of NRCov2-20-Fc and three
750 dilutions (1:5, 1:125, and 1:6,250) of pooled positive and negative serum samples were included in
751 quadruplicate on each plate. Serum-free/ACE2-free and serum-free wells were also included on each
752 plate to establish the minimum and maximum signals, respectively. Plates were washed, and samples
753 and controls (20 µL) were added to the wells and incubated for 2 h. Plates were then washed, and 6.5
754 ng of ACE2-BAP diluted in 1% w/v skim milk powder in PBST was added to each well and incubated for
755 1 h. Plates were again washed, and Streptavidin-Peroxidase Polymer (Sigma #S2438), diluted in 1%
756 w/v skim milk powder in PBST at a concentration of 1.25 ng µL⁻¹ (25 ng/well) was added to each well
757 and incubated for 1 h. Plates were washed a final time and 20 µL of ELISA Pico Chemiluminescent
758 Substrate (diluted 1:2 in MilliQ H₂O) was dispensed into each well. After a 5-min incubation, plates
759 were read on an Neo2 plate reader (BioTek Instruments) at 20 ms/well and a read height of 1.0 mm.
760 Assay optimization data are presented in Supplementary Figure 14.

761

762 **Data analysis: Toronto**

763 Quality control and determination of relative ratios: Raw values for each sample (luminescence
764 counts per second) were normalized to a blank-subtracted reference point from the reference curve
765 ($0.0156 \mu\text{g mL}^{-1}$ for VHH72-Fc (for spike/RBD) or $0.0625 \mu\text{g mL}^{-1}$ for anti-N (for N)) to create relative
766 ratios. For each automated test, the raw values and relative ratios of each control were compared to
767 those of prior tests to confirm their similarity. The distributions of the raw values of the reference
768 points and positive controls compared to the blanks and the reference points for each antigen
769 compared to each other should be within the 90% confidence ellipse of the distributions of previous
770 tests. In addition, the reference points should be within 15% coefficient of variation (CV) of prior runs.
771 The \log_{10} sample density distributions of the raw values and relative ratios were compared to prior
772 runs to confirm that they were within range. For points outside of these ranges, the individual control
773 was either removed (e.g. if it was a single outlier out of the four on the plate) or the plate or test was
774 repeated.

775
776 Receiver-operating characteristic (ROC) analysis: Samples acquired prior to November 2019 (pre-
777 COVID) were considered true negatives and samples from convalescent patients with PCR-confirmed
778 COVID-19 were considered true positives (for IgM and IgA analyses, we selected positives that were
779 collected 20–40 d post-symptom onset). ROC analysis using relative ratios was performed with the
780 pROC package in R⁴⁹ with default parameters. For IgG (serum/plasma and DBS), the analysis was
781 performed in duplicate, with individual replicates considered individual samples. To avoid having
782 samples with technical errors skew the threshold determination, negative plasma samples that were
783 positive in only one replicate and negative DBS samples whose values were more than four standard
784 deviations (SDs) from the mean of the log distribution of negative samples were removed from the
785 analysis.

786
787 Thresholding based on the control mean: For plasma and serum IgG, negative controls (blanks, IgG
788 pools, 0.25 and $0.0625 \mu\text{L/well}$ of a negative master mix (including equal volumes of four pre-COVID-
789 19 samples (N2, N11, N39, N41), $n = 1,320$ for spike, $1,248$ each for RBD and N) from 23 experiments
790 over 4 months were included in the analysis. We used three SDs from the mean of the \log_{10}
791 distribution of the relative ratios of these negative controls as the threshold for each antigen. The
792 same strategy was employed for IgA (72 negative controls from two experiments 1 month apart) and
793 IgM (80 negative controls from three experiments over 2 months).

794
795 Scoring positives: Positive and negative results were first defined for each antigen, based on the
796 defined thresholds. For projects where an overall assessment of the confidence of antibody detection
797 in a sample is required, we imposed a sample-level rule: the sample must have passed positivity in at
798 least 2 out of 3 antigen tests.

799
800 Other data analyses: Plots were generated in R using the ggplot2, lattice, latticeExtra, grid, and
801 gridExtra packages. Correlations between samples were calculated using the cor() function in the R
802 stats package, using the Spearman method. The density distributions of the log of the signals scaled to
803 the reference were separated using the normalmixEM mixtool function in the R mixtools package,
804 based on an expected minimization of only two subpopulations assumed to have a Gaussian
805 distribution. normalmixEM initialization, mean, and SD parameters were based on visual estimation of
806 the density distribution of the log of the signal scaled to the reference. The initially assumed
807 proportion between the two subpopulations was set to 50%. Density distributions were plotted using

808 default R parameters (bandwidth: bw.nrd0, which implements a rule-of-thumb for choosing the
809 bandwidth of a Gaussian kernel density estimator).

810

811 Calibration to the WHO standard for antibody detection: For each antigen, the relative ratio from the
812 WHO International Standard (IS, National Institute for Biological Standards and Control (NIBSC, South
813 Mimms, United Kingdom), Code 20/136, pooled convalescent plasma) at different sample dilutions (in
814 binding antibody units (BAU) mL⁻¹) was represented in log-log scale. The response curve was modelled
815 by an S-shaped sigmoid curve ($y = a*x/(1+b*x)+c$, expressed in log(y), log(x) coordinates). The nls
816 function (nonlinear least squares) from the R stats package was used to best match the response to
817 the measured data. The interval where the log response was considered linear to the log of the BAU
818 mL⁻¹ was selected visually. The lm (linear model) function from the R stats package was used to obtain
819 the parameters of the linear approximation of the curve (Figure 3a). The WHO International
820 Reference panel (NIBSC code 20/268), which contains pooled plasma samples that are Negative (code
821 20/142), Low (code 20/140), Low S High N (code 20/144), Mid (code 20/148), and High (code 20/150),
822 was measured at different concentrations. Estimated BAU mL⁻¹ values were obtained from the above
823 linear approximation using only sample dilutions that were within this linear range, and further
824 adjusted by accounting for the dilution factor. To convert from relative ratios (RRs) to BAU mL⁻¹ for
825 plasma or serum samples where only the reference curve was included in the same test, (Figure 3d), a
826 conversion formula can be applied:

827

$$828 \log_2(\text{sample BAU mL}^{-1} \text{ at dilution fold } d) = (\log_2(\text{sample RR}) - a)/b + \log_2(d)$$

829

830 where a and b represent the y-intercept and slope of the linear interval of the IS curve
831 (Supplementary table 4).

832

833 Calibration to the WHO standard for snELISA: The WHO IS and the WHO International Reference
834 Panel were analyzed by snELISA at the indicated dilutions to convert values to International Units (IU
835 mL⁻¹). The same approach was applied as for the antibody detection ELISA except we used the sample
836 relative ratio (RR) instead of the log₂ of the sample RR because the linear range was larger. We then
837 applied this formula:

838

$$839 \log_2(\text{sample IU mL}^{-1} \text{ at dilution fold } d) = (\text{sample RR} - a)/b + \log_2(d)$$

840

841 where a and b represent the y-intercept and slope of the linear interval of the IS curve respectively
842 and d is the dilution factor of the sample. For RBD as antigen, a = 1.58 and b = -0.16.

843

844 **Data analysis: Ottawa**

845 For consistency in data processing, a constant plate layout was established, containing all controls and
846 standard curves in quadruplicate (Supplementary figure 11a). Luminescence values obtained from the
847 isotype- and antigen-specific standard curve were modeled using a four-parameter log-logistic
848 function to identify the inflection point (Supplementary figure 11b). Blank-subtracted luminescence
849 values were scaled in relation to the curve to allow data normalization for subsequent processing.
850 Using a 3% false discovery rate (FDR) calculated using a density distribution from a screen of adult and
851 pediatric pre-pandemic samples, a threshold was established for each isotype-antigen combination.
852 Signal to threshold (also known as signal-to-cutoff, S/CO) ratios specific to each isotype-antigen
853 combination were then calculated and sample positivity was determined (Supplementary figure 11c–

854 d). For example, for IgG, both spike and N antigens were considered. If respective antigens were
855 detected over the established threshold ($S/CO \geq 1$), a positive call was made. All analyses were
856 performed in R. Density distributions were determined using the default density function with default
857 parameters. Standard curve processing was performed using the LL.4 four-parameter log-logistic self-
858 starter function from the drc package⁵⁰, also with default parameters. Plots were generated using the
859 ggplot2 and reshape2 packages.

860
861 Using NML panel 4, containing known positive and negative DBS samples, the optimal FDR threshold
862 value for SARS-CoV-2 IgG-positive calls was determined by testing FDRs of 1–100% and calculating the
863 number of true positive (TP), false positive (FP), true negative (TN), and false negative (FN) samples.
864 Maximum accuracy occurred at an FDR of 3% (Supplementary figure 11e). ROC curves and associated
865 area under the curve measurements were generated in R using the pROC package with default
866 parameters (Table 2, Supplementary figure 11f–h).

867
868 To convert luminescence values into BAU mL^{-1} , the WHO IS was titrated for spike, RBD, and N
869 (Supplementary figure 9). Scaled luminescence was calculated, as above, and response curves were
870 modelled using the LL.4 four-parameter log-logistic self-starter function from the drc package with
871 default parameters. The interval where the scaled luminescence response curves were considered
872 linear to BAU was selected visually. Calibration of the three antigens was performed using the NIBSC
873 20/268 reference panel. The following formula was used to convert scaled luminescence values to
874 BAU mL^{-1} :

875
876
$$\text{BAU mL}^{-1} = e^{((\ln(((\text{Upper-Lower})/(\text{Scaled Luminescence-Lower})) - 1))/\text{Slope} + \ln(\text{EC50}))} * \text{dilution factor}$$

877
878 For snELISA, the WHO IS was titrated and ACE2-spike binding inhibition was reported as a function of
879 IUs. Blank adjusted luminescence values were converted to inhibition of ACE2-spike binding; maximal
880 signal (i.e. 0% inhibition) was measured in absence of convalescent plasma (1% w/v skim milk powder
881 in PBST). The normalized data was fitted using the LL.4 four-parameter log-logistic self-starter
882 function from the drc package with default parameters in R to correlate binding inhibition to IUs. The
883 following formula was used to convert binding inhibition % to IU mL^{-1} :

884
885
$$\text{IU mL}^{-1} = e^{((\ln(((\text{Upper-Lower})/(\% \text{inhibition-Lower})) - 1))/\text{Slope} + \ln(\text{EC50}))} * \text{dilution factor}$$

886 887 **Reagent access**

888 The reagents produced by the NRC and qualified as reference materials (spike [SMT1-1], N [NCAP-1]
889 and hACE2-BAP) are available through the Metrology Research Centre Virtual Store ([Virtual Store -
890 National Research Council Canada: Products in Category Proteins \(nrc-cnrc.gc.ca\)](https://www.nrc-cnrc.gc.ca/virtual-store)). A limited panel of
891 matched plasma and DBS is available upon request

892 893 **Code availability**

894 Code is available upon request.

895 896 **ACKNOWLEDGMENTS**

897 We thank Alex Pelletier, Denis L'Abbé, Mélanie Duchesne, Simon Lord-Dufour, Manon Ouimet, Brian
898 Cass, Louis Bisson, Alina Burlacu, Jean-Sébastien Maltais, Sergio Alpuche-Lazcano and other members
899 of the NRC-HHT Mammalian Cell Expression Section for their contribution to the cloning, expression

900 and purification of the various recombinant proteins used in this study. The contribution of Joline
901 Cormier to recombinant protein sample management is greatly appreciated. We are grateful to Joe
902 Schrag, Roger Maurice, and Mathieu Coutu from NRC-HHT (Montreal) for SEC-UPLC and SEC-HPLC
903 analyses. We thank Jamshid Tanha and Martin Rossotti from NRC-HHT (Ottawa) for providing
904 NRCov2-04-hFc1X7 and NRCov2-20-hFc1X7 antibodies. We thank Frank Sicheri and Derek Ceccarelli
905 (LTRI) for contributing bacterially expressed N and James Rini (University of Toronto) for contributing
906 RBD and biotinylated ACE2 protein to compare with the reagents described here. We also thank
907 Lauren Caldwell for preprocessing some of the data generated from automated ELISAs. We thank
908 Bruce Mazer, Mel Krajdén and members of the COVID-19 Immunity Task Force (CITF) for coordinating
909 immune response studies across the country and for supporting assay development and
910 implementation. This is NRC's publication #NRC-HHT_53561A. We acknowledge support from Ontario
911 Together and funding from the Canadian Institutes of Health Research (CIHR; #VR1-172711, GA1-
912 177703 and #439999) and the COVID-19 Immunity Task Force (CITF). We also acknowledge financial
913 support from the NRC's Pandemic Response Challenge Program. Funding for initial assay development
914 in the Gingras lab was provided through generous donations from the Royal Bank of Canada and the
915 Krembil Foundation to the Sinai Health System Foundation. The robotics equipment used is housed in
916 the Network Biology Collaborative Centre at the LTRI, a facility supported by the Canada Foundation
917 for Innovation, the Ontario Government, and Genome Canada and Ontario Genomics (OGI-139).
918 Assay development in the Langlois lab and the purchase of robotic equipment was supported by a
919 grant from the CIHR (#VR2-172722 and VS2 - 175569) and supplemental funding from the CITF. Kento
920 T Abe was a recipient of an Ontario Graduate Scholarship and is supported by a CIHR CGS-D
921 studentship. Yannick Galipeau is supported by a CIHR CGS-M studentship. Mariam Maltseva holds a
922 Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST). Anne-Claude Gingras
923 is the Canada Research Chair in Functional Proteomics, and Marc-André Langlois, Anne-Claude
924 Gingras, Jeffrey Wrana, and Samira Mubareka are members of CoVaRR-Net, the CIHR Coronavirus
925 Variants Rapid Response Network.

926

927 **Competing interests:** The authors declare no competing interests for this manuscript.

928

929 **Contributors:** Karen Colwill, Anne-Claude Gingras, Marc-André Langlois, and Yves Durocher conceived
930 the study. Karen Colwill, Anne-Claude Gingras, Marc-André Langlois, Matthew Stuiblé, Christian
931 Gervais, Yannick Galipeau, Corey Arnold, and Yves Durocher wrote the paper. Yves Durocher,
932 Matthew Stuiblé and Christian Gervais designed, performed, and validated reagent purification
933 procedures. Linda Bennett, Kevin Yau, Angel X Li, Aimee Paterson, Michelle A Hladunewich, Pamela J
934 Goodwin, Samira Mubareka, Allison J McGeer and Steven J Drews contributed essential patient
935 samples. Bhavisha Rathod was responsible for sample intake at the Toronto site. François Cholette,
936 Christine Mesa prepared and helped evaluate DBS panels and John Kim supervised the DBS panel
937 evaluation. Yannick Galipeau, Corey Arnold, Bhavisha Rathod, Jenny H Wang, Mariam Maltseva,
938 Mariam Iskilova, and Mahya Fazel-Zarandi performed serology experiments. Karen Colwill, Miriam
939 Barrios-Rodiles, Kento T Abe, Martin Pelchat, Lynda Rocheleau, Yannick Galipeau and Adrian
940 Pasculescu performed data analysis. Martin Pelchat and Adrian Pasculescu performed statistical
941 modelling. Karen Colwill, Kento T Abe, Adrian Pasculescu, Yannick Galipeau, Mariam Maltseva, Lynda
942 Rocheleau, Matthew Stuiblé and Martin Pelchat generated figures for the paper. Miriam Barrios-
943 Rodiles and Jeffrey L Wrana provided oversight of the Toronto screening facility.

944 All the authors gave final approval of the version to be published and agreed to be accountable for all
945 aspects of the work. Marc-André Langlois, Anne-Claude Gingras, and Yves Durocher are co-senior
946 corresponding authors.

947
948 **Data Sharing:** Raw and normalized values from the automated assays are provided in Supplementary
949 table 5. R scripts used to analyze the data are available upon request.

950

951

952

953 References

- 954 1. Johns Hopkins University COVID-19 Dashboard. [cited February 25 2021]. Available from:
955 <https://coronavirus.jhu.edu/map.html>.
- 956 2. Few Canadians had antibodies against SARS-CoV-2 in early 2021 - Statistics Canada. [updated
957 July 6 2021; cited February 25 2022]. Available from: [https://www150.statcan.gc.ca/n1/daily-](https://www150.statcan.gc.ca/n1/daily-quotidien/210706/dq210706a-eng.htm)
958 [quotidien/210706/dq210706a-eng.htm](https://www150.statcan.gc.ca/n1/daily-quotidien/210706/dq210706a-eng.htm).
- 959 3. Serotracker. [updated February 22 2022; cited February 25 2022]. Available from:
960 <https://serotracker.com/en/Explore>.
- 961 4. Chung H, He S, Nasreen S, *et al*. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines
962 against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada:
963 test negative design study. *BMJ* 2021; **374**: n1943.
- 964 5. Health Infobase Canada -COVID-19 Vaccination Coverage. [updated February 18 2022; cited
965 February 25 2022]. Available from: [https://health-infobase.canada.ca/covid-19/vaccination-](https://health-infobase.canada.ca/covid-19/vaccination-coverage/)
966 [coverage/](https://health-infobase.canada.ca/covid-19/vaccination-coverage/).
- 967 6. Van Caesele P, Canadian Public Health Laboratory N, Bailey D, *et al*. SARS-CoV-2 (COVID-19)
968 serology: implications for clinical practice, laboratory medicine and public health. *Cmaj* 2020;
969 **192**: E973-E979.
- 970 7. Favresse J, Eucher C, Elsen M, *et al*. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the
971 Analytical Kit: A Report for Up to 10 Months after Infection. *Microorganisms* 2021; **9**.
- 972 8. Isho B, Abe KT, Zuo M, *et al*. Persistence of serum and saliva antibody responses to SARS-CoV-
973 2 spike antigens in COVID-19 patients. *Science immunology* 2020; **5**.
- 974 9. Sherina N, Piralla A, Du L, *et al*. Persistence of SARS-CoV-2-specific B and T cell responses in
975 convalescent COVID-19 patients 6-8 months after the infection. *Med (N Y)* 2021; **2**: 281-295
976 e284.
- 977 10. Dan JM, Mateus J, Kato Y, *et al*. Immunological memory to SARS-CoV-2 assessed for up to 8
978 months after infection. *Science (New York, NY)* 2021; **371**.
- 979 11. Gallais F, Gantner P, Bruel T, *et al*. Evolution of antibody responses up to 13 months after
980 SARS-CoV-2 infection and risk of reinfection. *EBioMedicine* 2021; **71**: 103561.
- 981 12. Feng C, Shi J, Fan Q, *et al*. Protective humoral and cellular immune responses to SARS-CoV-2
982 persist up to 1 year after recovery. *Nat Commun* 2021; **12**: 4984.
- 983 13. Abe KT, Li Z, Samson R, *et al*. A simple protein-based surrogate neutralization assay for SARS-
984 CoV-2. *JCI Insight* 2020; **5**.
- 985 14. Mattiuzo G, Bentley E, Hassall M, *et al*. Establishment of the WHO International Standard and
986 Reference Panel for anti-SARS-CoV-2 antibody. WHO Expert Committee on Biological
987 Standardization. WHO/BS/2020.2403. In: Organization WH, editor. 2020.

- 988 15. Stuible M, Gervais C, Lord-Dufour S, *et al.* Rapid, high-yield production of full-length SARS-CoV-
989 2 spike ectodomain by transient gene expression in CHO cells. *J Biotechnol* 2021; **326**: 21-27.
- 990 16. Ye Q, West AMV, Silletti S, Corbett KD. Architecture and self-assembly of the SARS-CoV-2
991 nucleocapsid protein. *Protein Sci* 2020; **29**: 1890-1901.
- 992 17. Wrapp D, De Vlioger D, Corbett KS, *et al.* Structural Basis for Potent Neutralization of
993 Betacoronaviruses by Single-Domain Camelid Antibodies. *Cell* 2020; **181**: 1436-1441.
- 994 18. Morley GL, Taylor S, Jossi S, *et al.* Sensitive Detection of SARS-CoV-2-Specific Antibodies in
995 Dried Blood Spot Samples. *Emerg Infect Dis* 2020; **26**: 2970-2973.
- 996 19. Biosafety advisory: SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2) -
997 Government of Canada. [updated November 23 2021; cited February 25 2022]. Available from:
998 [https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/biosafety-](https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/biosafety-directives-advisories-notifications/novel-coronavirus-january-27.html)
999 [directives-advisories-notifications/novel-coronavirus-january-27.html](https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/biosafety-directives-advisories-notifications/novel-coronavirus-january-27.html).
- 1000 20. Galipeau Y, Siragam V, Laroche G, *et al.* Relative Ratios of Human Seasonal Coronavirus
1001 Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2.
1002 *EBioMedicine* 2021; **74**: 103700.
- 1003 21. Yau K, Abe KT, Naimark D, *et al.* Evaluation of the SARS-CoV-2 Antibody Response to the
1004 BNT162b2 Vaccine in Patients Undergoing Hemodialysis. *JAMA Netw Open* 2021; **4**: e2123622.
- 1005 22. Feng S, Phillips DJ, White T, *et al.* Correlates of protection against symptomatic and
1006 asymptomatic SARS-CoV-2 infection. *Nature medicine* 2021; **27**: 2032-2040.
- 1007 23. Approved COVID-19 Vaccines - Government of Canada. [updated February 24 2022; cited
1008 February 25 2022]. Available from: [https://www.canada.ca/en/health-canada/services/drugs-](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines.html)
1009 [health-products/covid19-industry/drugs-vaccines-treatments/vaccines.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines.html).
- 1010 24. Approved COVID-19 Vaccines - US Food and Drug Administration. [updated February 11 2022;
1011 cited February 25 2022]. Available from: [https://www.fda.gov/emergency-preparedness-and-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines)
1012 [response/coronavirus-disease-2019-covid-19/covid-19-vaccines](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines).
- 1013 25. COVID-19 approved vaccines - European Medicines Agency. [cited February 25 2022].
1014 Available from: [https://www.ema.europa.eu/en/human-regulatory/overview/public-health-](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines)
1015 [threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines).
- 1016 26. Duarte N, Yanes-Lane M, Arora RK, *et al.* Adapting Serosurveys for the SARS-CoV-2 Vaccine
1017 Era. *Open Forum Infect Dis* 2022; **9**: ofab632.
- 1018 27. Lv H, Wu NC, Tsang OT, *et al.* Cross-reactive Antibody Response between SARS-CoV-2 and
1019 SARS-CoV Infections. *Cell Rep* 2020; **31**: 107725.
- 1020 28. Ou X, Liu Y, Lei X, *et al.* Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
1021 its immune cross-reactivity with SARS-CoV. *Nat Commun* 2020; **11**: 1620.
- 1022 29. Dobano C, Santano R, Jimenez A, *et al.* Immunogenicity and crossreactivity of antibodies to the
1023 nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity
1024 studies. *Transl Res* 2021; **232**: 60-74.
- 1025 30. Rogers TF, Zhao F, Huang D, *et al.* Isolation of potent SARS-CoV-2 neutralizing antibodies and
1026 protection from disease in a small animal model. *Science (New York, NY)* 2020; **369**: 956-963.
- 1027 31. Premkumar L, Segovia-Chumbez B, Jadi R, *et al.* The receptor binding domain of the viral spike
1028 protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.
1029 *Science immunology* 2020; **5**.
- 1030 32. Science Brief: Omicron (B.1.1.529) Variant. [updated December 2 2021; cited February 25
1031 2022]. Available from: [https://www.cdc.gov/coronavirus/2019-ncov/science/science-](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html)
1032 [briefs/scientific-brief-omicron-variant.html](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html).

- 1033 33. Tuite AR, Fisman D, Abe KT, *et al.* Estimating SARS-CoV-2 Seroprevalence in Canadian Blood
1034 Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays. *Microbiol Spectr*
1035 2022; **10**: e0256321.
- 1036 34. Saeed S, O'Brien SF, Abe K, *et al.* Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
1037 2) seroprevalence: Navigating the absence of a gold standard. *PloS one* 2021; **16**: e0257743.
- 1038 35. Tang X, Sharma A, Pasic M, *et al.* Assessment of SARS-CoV-2 Seropositivity During the First and
1039 Second Viral Waves in 2020 and 2021 Among Canadian Adults. *JAMA Netw Open* 2022; **5**:
1040 e2146798.
- 1041 36. CanPath National Study. [updated June 23 2021; cited February 25 2022]. Available from:
1042 [https://canpath.ca/2021/06/early-results-from-canpaths-national-study-confirm-antibody-](https://canpath.ca/2021/06/early-results-from-canpaths-national-study-confirm-antibody-levels-are-stronger-after-receiving-two-doses-of-covid-19-vaccine)
1043 [levels-are-stronger-after-receiving-two-doses-of-covid-19-vaccine.](https://canpath.ca/2021/06/early-results-from-canpaths-national-study-confirm-antibody-levels-are-stronger-after-receiving-two-doses-of-covid-19-vaccine)
- 1044 37. Walmsley S, Szadkowski L, Wouters B, *et al.* Safety and Efficacy of Preventative COVID
1045 Vaccines: The StopCoV Study. *medRxiv* 2022: 2022.2002.2009.22270734.
- 1046 38. Dayam RM, Law JC, Goetgebuer RL, *et al.* Antibody and T cell responses to SARS-CoV-2 mRNA
1047 vaccines during maintenance therapy for immune-mediated inflammatory diseases. *medRxiv*
1048 2022: 2022.2001.2026.22269856.
- 1049 39. Yau K, Chan CT, Abe KT, *et al.* Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-
1050 BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. *Cmaj*
1051 2022.
- 1052 40. Abe KT, Hu Q, Mozafarihashjin M, *et al.* Neutralizing antibody responses to SARS-CoV-2
1053 variants in vaccinated Ontario long-term care home residents and workers. *medRxiv Preprint*
1054 2021: 2021.2008.2006.21261721.
- 1055 41. Vinh DC, Gouin J-P, Cruz-Santiago D, *et al.* Real-world serologic responses to Extended-interval
1056 and Heterologous COVID-19 mRNA vaccination in Frail Elderly - Interim report from a
1057 prospective observational cohort study. *medRxiv Preprint* 2021: 2021.2009.2016.21263704.
- 1058 42. CITF Funded Projects. [cited February 24 2022]. Available from:
1059 [https://www.covid19immunitytaskforce.ca/task-force-](https://www.covid19immunitytaskforce.ca/task-force-research/#:~:text=Our%20Funded%20Research,Cutting%20Themes%2C%20and%20Immunity%20Modelling)
1060 [research/#:~:text=Our%20Funded%20Research,Cutting%20Themes%2C%20and%20Immunity](https://www.covid19immunitytaskforce.ca/task-force-research/#:~:text=Our%20Funded%20Research,Cutting%20Themes%2C%20and%20Immunity%20Modelling)
1061 [%20Modelling.](https://www.covid19immunitytaskforce.ca/task-force-research/#:~:text=Our%20Funded%20Research,Cutting%20Themes%2C%20and%20Immunity%20Modelling)
- 1062 43. Shi C, Shin YO, Hanson J, Cass B, Loewen MC, Durocher Y. Purification and characterization of a
1063 recombinant G-protein-coupled receptor, *Saccharomyces cerevisiae* Ste2p, transiently
1064 expressed in HEK293 EBNA1 cells. *Biochemistry* 2005; **44**: 15705-15714.
- 1065 44. Dorion-Thibaudeau J, St-Laurent G, Raymond C, De Crescenzo G, Durocher Y. Biotinylation of
1066 the Fcγ receptor ectodomains by mammalian cell co-transfection: application to the
1067 development of a surface plasmon resonance-based assay. *J Mol Recognit* 2016; **29**: 60-69.
- 1068 45. Darnell ME, Taylor DR. Evaluation of inactivation methods for severe acute respiratory
1069 syndrome coronavirus in noncellular blood products. *Transfusion* 2006; **46**: 1770-1777.
- 1070 46. Cholette F, Mesa C, Harris A, *et al.* Dried blood spot specimens for SARS-CoV-2 antibody
1071 testing: A multi-site, multi-assay comparison. *PloS one* 2021; **16**: e0261003.
- 1072 47. Amanat F, Stadlbauer D, Strohmeier S, *et al.* A serological assay to detect SARS-CoV-2
1073 seroconversion in humans. *Nature medicine* 2020; **26**: 1033-1036.
- 1074 48. Amanat F, Stadlbauer D, Strohmeier S, *et al.* A serological assay to detect SARS-CoV-2
1075 seroconversion in humans. *Nature medicine* 2020.
- 1076 49. Robin X, Turck N, Hainard A, *et al.* pROC: an open-source package for R and S+ to analyze and
1077 compare ROC curves. *BMC bioinformatics* 2011; **12**: 77.

1078 50. Ritz C, Baty F, Streibig JC, Gerhard D. Dose-Response Analysis Using R. *PloS one* 2015; **10**:
1079 e0146021.

1080

1081 **Figure Legends**

1082

1083 **Figure 1.** High-quality reagents for SARS-CoV-2 serology. **(a)** Reagents comprising the protein toolbox
1084 (left panel) are used in high-throughput plate-based ELISAs for antibody detection and surrogate
1085 neutralization (right panel). **(b)** The reagents were analyzed on Coomassie-stained polyacrylamide gels
1086 under reducing conditions to assess their purity. Molecular weight markers (kDa) are shown to the
1087 left of the gels.

1088

1089 **Figure 2.** Development of high-throughput ELISAs for plasma or serum. **(a)** Known negative (pre-
1090 COVID-19) and positive (confirmed convalescent) samples (0.0625 $\mu\text{L}/\text{well}$) were tested in an
1091 automated antibody detection ELISA in two separate replicates 7 weeks apart. Spearman correlations
1092 are noted. **(b)** Density distributions of negative samples were plotted for each antigen. The black lines
1093 represent the mean of the negative distribution (dotted) and three SDs from the mean (solid; the
1094 relative ratio is indicated). The blue line represents the thresholds established by ROC analysis. **(c)**
1095 Comparison of the antigens with a set of known negative and positive samples at 0.0625 $\mu\text{L}/\text{well}$.
1096 Spearman correlations are shown. For both (a) and (c), dashed lines represent the thresholds as
1097 defined by the 3-SD negative distribution shown in (b) and listed in Table 1.

1098

1099 **Figure 3.** Conversion of Ottawa and Toronto ELISA data to WHO BAUs and comparison to the WHO
1100 Reference Panel 20/268. **(a)** The 20/268 reference panel at the indicated dilutions (arrows) was fitted
1101 onto a dose-response curve of the IS with the measured values expressed as relative ratios (Toronto).
1102 A 1:160 dilution (0.0625 $\mu\text{L}/\text{well}$) of sample was used except when it was out of the linear range of the
1103 fitted line in which case the 1:2560 dilution (0.0039 $\mu\text{L}/\text{well}$) was used. **(b)** IgG levels in the five
1104 samples in the 20/268 reference panel are represented for spike, its RBD, and N ($n = 12$, 4 replicates
1105 at 1:500, 1:1,000, 1:2,500 dilutions). **(c)** Box plots for Ottawa (orange) show the median of the 12
1106 samples from B. Box plots for Toronto (blue) show the median of individual measurements ($n = 4$) for
1107 the selected dilution (1:2560 (0.0039 $\mu\text{L}/\text{well}$) for Mid and High for spike and N, High for RBD, the rest
1108 were at 1:160 (0.0625 $\mu\text{L}/\text{well}$)). The WHO bar graph shows the geometric mean from the WHO study
1109 and the lines with half arrows represent a 0.5–2-fold range from the geometric mean. **(d)** Reference
1110 curves (VHH72-Fc for spike/RBD, anti-N for N) were plotted for each antigen either from the same
1111 tests in which the IS was analyzed or from 25 different tests over 3 months (shown as faded black
1112 lines with a thicker median line in black). The blue dashed lines represent the limits of the linear
1113 intervals for the curves and the pink arrows represent the BAU mL^{-1} at those points. As the reference
1114 curves are parallel to the IS within the linear interval, a conversion factor can be applied to convert
1115 relative ratios to international BAU mL^{-1} units (Supplementary table 4). For illustrations purposes to
1116 show IS and reference curves in the same panel, the X-axis is BAU mL^{-1} for IS and $\mu\text{g mL}^{-1} * 100$ for the
1117 reference curves.

1118

1119 **Figure 4.** Dose response curves or single-point snELISA and conversion to International Units using the
1120 Who International Standard. **(a)** Correlation of spike to RBD as snELISA antigens is shown for 11
1121 samples in a 10-point dilution series (individual curves are shown in Supplementary figure 13). **(b)**
1122 Dose response curves ($n = 4$) for the spike snELISA. Samples were from convalescent SARS-CoV-2

1123 individuals 3 weeks after 1 or 2 doses of Comirnaty vaccine (Pfizer) or an uninfected individual (from a
1124 surveillance study) 3 weeks post-first dose of Comirnaty. Pooled sera were from 100 individuals with
1125 or without prior SARS-CoV-2 infection. **(c)** Single point measurements (at 1:5 dilution) using the spike
1126 snELISA. **(d)** Titration of the neutralizing activity of the WHO IS using snELISA. Raw luminescence
1127 values were converted to inhibition of ACE2-Spike binding; maximal signal (i.e. 0% inhibition) was
1128 measured in absence of convalescent plasma (PBS only). The normalized data was fitted with a four-
1129 parameter logistic function and the 95% confidence interval (IC95) and two standard deviations (2SD)
1130 is shown. **(e)** Box plots for the WHO reference panel 20/268 using RBD (blue, Toronto, ACE2 source:
1131 Rini) or spike (orange, Ottawa) as antigens. For RBD, $n = 3$ at 1:10 dilution for Low, $n = 4$ at 1:10
1132 dilution for Mid, $n = 7$ at 1:40 and 1:160 for High. For spike, $n = 12$ for High (4 replicates at 3
1133 dilutions), $n = 8$ for LowS HighN and Mid (4 replicates at 2 dilutions) and $n = 4$ for Low (2 replicates at
1134 2 dilutions). The WHO bar graph shows the geometric mean from the WHO study and the lines with
1135 half arrows represent a 0.5–2-fold range from the geometric mean. No inhibition was seen for the
1136 LowS HighN sample for RBD.

1137

1138 **Figure 5.** Visualization of Data from 3 Antigen testing. The results from the three antigens with known
1139 negative and positive samples **(a)** and samples from a longitudinal study of patients on dialysis at
1140 baseline and after their first vaccine dose **(b)**. The dashed lines represent the thresholds for spike and
1141 N. The area with positives for both spike and N (colored in gray) is indicative of natural infection and
1142 the area showing samples that are N-negative but spike-positive (and RBD-positive if colored) is
1143 highlighted in green on the right panel and is indicative of vaccination.

1144

1145

1146
1147

Table 1. ELISA performance statistics for plasma or serum IgG (Toronto)

	spike	RBD	N	≥ 2 positive antigens
ROC analysis				
AUC	0.978	0.974	0.964	n/a
Threshold (Cut Point)	0.195	0.073	0.349	n/a
FPR	0.009	0.009	0.009	0.000
TPR	0.944	0.921	0.811	0.931
3 SDs from the mean of the negative controls				
Threshold	0.190	0.186	0.396	n/a
FPR	0.011	0.000	0.007	0.000
TPR	0.944	0.890	0.786	0.912
Samples used to assess performance †				
Sample cohort	Replicates	Number	Total	
Patients with COVID-19	1	211	392	
	2	181		
Pre-COVID-19 (negative)	1	300 for N and spike, 296 for RBD	560	
	2	260 for N and RBD, 258 for spike		

1148 †Negative samples were excluded from the analysis for spike and RBD if one replicate was positive.

1149
1150

1151 **Table 2. ROC statistics for the DBS IgG ELISA (Ottawa)**

Antigen	spike	RBD	N	≥ 2 positive antigens
AUC	0.991	0.996	0.992	N/A
Threshold (Cut Point)	1.410	0.868	1.171	N/A
FPR	0.02	0.01	0.06	0.02
TPR	1.00	1.00	1.00	0.98
Number of samples used to generate ROC curves[†]				
Antigen	spike	RBD	N	≥ 2 positive antigens
Patients with COVID-19	97	97	97	97
Number excluded	2	2	2	2
Total analyzed	95	95	95	95
Pre-COVID-19 (negative)	90	90	90	90
Number excluded	0	0	0	0
Total analyzed	90	90	90	90

1152 [†]NML panel 4. Each sample was analyzed once, and thresholds were defined at 3% FDR as described
 1153 in Supplementary figure 11. Two positive samples were excluded as they were early on in infection.
 1154
 1155

1156 **Table 3.** ROC statistics for the DBS IgG ELISA (Toronto)

Antigen	spike	RBD	N	≥ 2 positive antigens
AUC	0.99	0.99	0.99	N/A
Threshold (Cut point)	0.482	0.324	0.642	N/A
FPR	0.01	0.01	0.01	0.00
TPR	0.98	0.98	0.92	0.98
Number of samples used to generate ROC curves[†]				
Antigen	spike	RBD	N	≥ 2 positive antigens
Patients with COVID-19	97	97	97	97
Number excluded	0	0	0	0
Total analyzed	97	97	97	97
Pre-COVID-19 (negative)	90	90	90	90
Number excluded	3	1	2	4
Total analyzed	87	89	88	86

1157 [†]NML panel 4. Each sample was analyzed in duplicate (the unique numbers of samples are shown).
 1158 Replicates were treated as separate samples in the ROC analysis. Negative samples were excluded
 1159 from the analysis if the replicates were > 4 SDs from the mean.

1160

1161 **Supplementary figures**

1162

1163 Supplementary figure 1 – Chromatogram traces for the purified ELISA antigens and detection
1164 reagents.

1165 Supplementary figure 2 – Purification of recombinant anti-spike antibodies.

1166 Supplementary figure 3 – Titration curves of 32 serum samples from CBS using automated ELISAs to
1167 detect (a) spike, (b) RBD 331–521, and (c) N antibodies.

1168 Supplementary figure 4 – Performance of the IgG chemiluminescent ELISAs with plasma and serum.

1169 Supplementary figure 5 – Comparison between o-Phenylenediamine dihydrochloride (OPD) and
1170 3,3',5,5'-tetramethylbenzidine (TMB) as colorimetric substrates for the
1171 manual 96-well plate ELISA.

1172 Supplementary figure 6 – Comparison of IgG-HRP secondary antibody performance (a) Analysis of NRC
1173 IgG-HRP secondary (detection) antibodies.

1174 Supplementary figure 7 – Elution and secondary antibody optimizations for IgG ELISAs using DBSs.

1175 Supplementary figure 8 – IgA and IgM ELISAs.

1176 Supplementary figure 9 – Conversion of serology data to WHO BAUs and validation of SARS-CoV-2
1177 IgG profiling performed on the uOttawa automated serology platform.

1178 Supplementary figure 10 – DBS optimization.

1179 Supplementary figure 11 – Processing and validation of the Ottawa automated serology platform.

1180 Supplementary figure 12 – ROC curve for panel 4 DBS IgG analysis.

1181 Supplementary figure 13 – Optimization and testing of NRC reagents for snELISA.

1182 Supplementary figure 14 – Optimization of the snELISA for the automated platform.

1183 Supplementary figure 15 – Optimized snELISA for the automated platform.

1184 Supplementary figure 16 – Optimization of the NRC reagents.

1185 Supplementary figure 17 – Optimization of IgG#5-HRP and recombinant antibodies for
1186 chemiluminescent assays

1187

1188

1189 **Supplementary Tables**

1190

1191 Supplementary table 1 – Reagent information.

1192 Supplementary table 2 – Comparison of manual and automated ELISAs.

1193 Supplementary table 3 – ELISA performance statistics for plasma or serum IgA and IgM (Toronto).

1194 Supplementary table 4 – Conversion of relative ratios to international units (BAU mL⁻¹) for plasma or
1195 serum.

1196 Supplementary table 5 – Raw data from automated experiments.

1197









